Composition for the treatment of CFTR-mediated diseases
Stable and bioavailable granule compositions of Banjacafter, Tezacafter, and Dutivacafter address the challenges of pediatric cystic fibrosis treatment by ensuring accurate dosing and palatability, improving dispersibility and bioavailability.
Patent Information
- Application Number
- KR1020267029225
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-07
- Filing Date
- 2025-02-06
- Publication Date
- 2026-11-10
AI Technical Summary
Existing pharmaceutical compositions for treating cystic fibrosis in children face challenges such as difficulty in swallowing, dosing inaccuracies, manufacturing reproducibility, dispersion issues, palatability, and bioavailability, particularly for CFTR modulators like Banjacafter, Tezacafter, and Dutivacafter.
Development of stable and bioavailable pharmaceutical granule compositions comprising Banjacafter, Tezacafter, and Dutivacafter, formulated with excipients to ensure accurate dosing, rapid dispersion, and high palatability, packaged in unit doses suitable for pediatric administration.
The granule compositions provide consistent and accurate delivery of low doses with improved dispersibility, physical and chemical stability, and high bioavailability, addressing the challenges of pediatric administration.
Smart Images

Figure PCT00033_ABST
Abstract
Description
Technology Field
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 550,817 filed on February 7, 2024, the contents of which are incorporated by reference in their entirety. Background Technology
[0002] The present invention relates to calcium bis((14 S )-8-[3-(2-{Disspiro[2.0.2 4 .1 3 ]heptane-7-yl}ethoxy)pyrazole-1-yl]-12,12-dimethyl-2,2,4-trioxo-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11 , 14 .0 5 , 10 ]tetracosa-1(23),5,7,9,19,21-hexaen-3-id), ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -Indole-5-il)cyclopropanecarboxamide, and N -(2-( Burst The invention relates to a plurality of granular pharmaceutical compositions suitable for administration to children containing -butyl)-5-hydroxy-4-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, comprising a formulation of the granules, a method for manufacturing and processing the granules, and a method for treating cystic fibrosis using the pharmaceutical compositions.
[0003] One aspect of the present invention provides granules suitable for pediatric administration comprising a modulator of a cystic fibrosis transmembrane conductivity modulator (CFTR). Cystic fibrosis (CF) is a recessive genetic disease affecting approximately 70,000 children and adults worldwide. Despite progress in the treatment of CF, there is no cure.
[0004] In patients with CF, mutations in endogenously expressed CFTR in the respiratory epithelium result in reduced apical anion secretion, causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to increased mucus accumulation in the lungs and ultimately to concomitant microbial infections that lead to death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that are fatal if left untreated. Furthermore, a significant number of men with cystic fibrosis are infertile, and fertility is reduced among women with cystic fibrosis.
[0005] Sequence analysis of the CFTR gene has identified various disease-causing mutations (Cutting, GR et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, BS. et al. (1989) Science 245:1073-1080; Kerem, BS et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, more than 2,000 mutations have been identified in the CF gene; currently, the CFTR2 database contains information on only 485 of these identified mutations, and there is sufficient evidence to define 401 mutations as disease-causing mutations. The most common disease-causing mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, commonly referred to as the F508del mutation. This mutation occurs in many cases of cystic fibrosis and is associated with severe disease.
[0006] The deletion of residue 508 in CFTR prevents the initial protein from folding correctly. This results in the mutant protein being unable to exit the endoplasmic reticulum (ER) and move to the plasma membrane. Consequently, the number of CFTR channels for anion transport present in the membrane is significantly lower than that observed in cells expressing wild-type CFTR, i.e., CFTR without the mutation. In addition to impaired mobility, the mutation results in defective channel gating. Taken together, the reduced number of channels in the membrane and defective gating lead to reduced anion and fluid transport through the epithelium (Quinton, PM (1990), FASEB J. 4: 2709-2727). Channels defective due to the F508del mutation are less functional than wild-type CFTR channels, but are still functional. (Dalemans et al. (1991), Nature London. 354: 526-528; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to F508del, other disease-causing mutations in CFTR resulting in defective mobility, synthesis, and / or channel gating can be upregulated or downregulated to alter anion secretion and modify disease progression and / or severity.
[0007] CFTR is a cAMP / ATP-mediated anion channel expressed in various cell types, including absorptive and secretory epithelial cells, where it regulates anion flux across membranes as well as the activity of other ion channels and proteins. In epithelial cells, the normal function of CFTR is important for maintaining electrolyte transport throughout the body, including respiratory and digestive tissues. CFTR consists of approximately 1,480 amino acids, encoding a protein composed of tandem repeats of transmembrane domains, each containing six transmembrane helices and nucleotide-binding domains. The two transmembrane domains are linked by a large, polar regulatory (R)-domain containing multiple phosphorylation sites that regulate channel activity and cell movement.
[0008] Chloride transport is mediated by ENaC and CFTR present in the apical membrane and Na expressed on the basal side of the cell. + -K + It occurs through the cooperative activity of ATPase pumps and Cl- channels. The secondary active transport of chloride from the lumen side leads to the accumulation of intracellular chloride, which subsequently Cl - Cells can be passively ejected through channels, which can lead to vectorial transport. Na on the basal side + / 2Cl - / K + Co-transporter, Na + -K + - ATPase pump and basolateral membrane K + The arrangement of channels and the CFTRs on the lumen side cooperatively regulate the secretion of chloride through the CFTRs on the lumen side. Since water is likely not actively transported on its own, its flow through the epithelium depends on the fine interepithelial osmotic gradient created by the bulk flow of sodium and chloride.
[0009] (14 S)-8-[3-(2-{disspiro[2.0.2.1]heptane-7-yl}ethoxy)-1 H -pyrazol-1-yl]-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo [17.3.1.1 11,14 .0 5,10 ]Tetracosa-1(22),5,7,9,19(23),20-hexane-2,2,4-trione (banjacarfter), calcium bis((14 S )-8-[3-(2-{Disspiro[2.0.2 4 .1 3 ]heptane-7-yl}ethoxy)pyrazole-1-yl]-12,12-dimethyl-2,2,4-trioxo-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11 , 14 .0 5 , 10 ]tetracosa-1(23),5,7,9,19,21-hexaen-3-ide) (banjacarpter calcium salt), and ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -Indole-5-1)cyclopropanecarboxamide (Tezacarfter) is a potent and selective CFTR corrector for treating mutant forms of human CFTR-mediated diseases such as cystic fibrosis. N -(2-( Burst -butyl)-5-hydroxy-4-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Dutivacarfter) is a potent and selective CFTR enhancer of human CFTR in wild and mutant forms and is useful for the treatment of cystic fibrosis.
[0010] Pediatric patients with CF may require the administration of pharmaceutical compositions in dosage forms that facilitate swallowing or can be easily mixed with easily digestible foods. The use of powders and crushed tablets in the administration of pharmaceutical compositions to children has often presented problems in administration and dosage. Some of the challenges associated with the development of pediatric formulations containing CFTR modulators are summarized below.
[0011] Ease of administration
[0012] Tablets and capsules are often very difficult for children to swallow. Therefore, alternative formulations that are easy to swallow, such as liquid formulations or suspensions, can facilitate administration. However, the practicality of liquid formulations and suspensions is limited when the water solubility of the active pharmaceutical ingredient is low.
[0013] Dosage accuracy
[0014] Administering crushed tablet formulations to children can cause absorption problems and may result in fragments that are too difficult to swallow or remain undigested and unsolubilized, leading to treatment failure or dosing inaccuracies. Additionally, the administration of crushed tablets can lead to dosing inaccuracies due to the difficulties associated with handling them. The use of powder mixtures can also result in dosing inaccuracies. In other instances, active powder formulations may remain attached to the inner walls of capsules, pouches, or packets upon administration, potentially resulting in a deficiency of the required therapeutic dose. Such dosing inaccuracies occur particularly frequently when the administerer is inexperienced and when low doses are used, such as in the treatment of pediatric patients. Therefore, dosing errors involving CF pharmaceutical active formulations are a significant issue in the pediatric population, especially considering that pharmaceutical CF active formulations are administered at low doses (e.g., less than 100 mg or less than 50 mg per unit dose). These dosing inaccuracies become fatal to pediatric patients who have a low threshold for dose deviation. The dose per administration of the pharmaceutical compound of the present invention is very low (the total unit dose of banzakarptor is about 12 mg or less, for example, the total unit dose is about 1 mg, about 2 mg, about 4 mg, about 6 mg, about 8 mg, about 10 mg, or about 12 mg). Administering multiple granules of low doses of the active pharmaceutical ingredient(s) exacerbates the possibility of dosing inaccuracies, because each individual granule must contain a specific fraction of the total unit dose. Therefore, there is a need to develop a pharmaceutical composition that provides a constant dose of a minute amount of medicine with minimal deviation.
[0015] Manufacturing reproducibility
[0016] During the manufacture of compressed solid dosage forms, such as granules, physical force is used to eject the dosage form from the die. The composition needs to be formulated to be hard enough to withstand the ejection force without the granules breaking. High ejection forces occur when there is significant friction between the compressed dosage form and the wall of the die. High ejection forces are undesirable because they can cause damage to the dosage form during ejection from the die and also lead to premature wear of the compression equipment (which itself can lead to reproducibility issues).
[0017] Dispersion
[0018] A potential method for administering CFTR-modulating compounds to pediatric patients is to mix the dosage form with a liquid or soft food. For this to be feasible, the dosage form must be soft enough to be rapidly broken down and dispersed in the mouth or within a medium of administration.
[0019] Preference
[0020] Palatability (e.g., aroma, taste, texture, and mouthfeel) is a critical factor in achieving acceptable dosing compliance for pediatric formulations. CFTR modulators can exhibit an unpleasant or bitter taste. For example, ivacarfter, a CFTR modulator, has a strong bitter taste. Therefore, formulations containing specific amounts of sweeteners and / or flavoring agents to mask this unpleasant or bitter taste are often required to achieve satisfactory patient compliance. At the same time, sweeteners or mixtures of sweeteners can impart an undesirable mouthfeel. For example, a mixture of mannitol and sucrose containing aspartame was found to have a "gritty" texture, despite an excellent flavor profile, making it unsuitable for pediatric formulations containing ivacarfter.
[0021] Physical and chemical stability
[0022] The physical and chemical stability of pharmaceutical granule compositions depends significantly on the specific formulation used. If a composition is not properly formulated, this can lead to undesirable chemical or physical changes, such as the conversion of the active pharmaceutical ingredient into a solid form with lower bioavailability.
[0023] Bioavailability
[0024] All of the above factors must be optimized without compromising bioavailability. Bioavailability is highly unpredictable, and any change in formulation can unexpectedly lead to a decrease in bioavailability.
[0025] Therefore, there is a need for pharmaceutical granule compositions of Banjacafter, Tejacafter, and Dutivacafter that are useful for treating pediatric patients with CF, wherein the compositions are physically and chemically stable, bioavailable, and consistently deliver specific doses present in very small amounts, all of which are sufficiently solid to be consistently manufactured and can be rapidly dispersed to provide acceptable solubility and bioavailability upon administration. The compositions of the present invention have been developed to balance all of these factors and satisfy all of these requirements.
[0026] There is a need for stable and bioavailable pharmaceutical granule compositions of Banzakafter, Tezakafter, and Dutivakafter that are useful for treating specific groups with unmet medical needs who cannot swallow adult tablets, such as children aged 12 to 24 months and 2 to 5 years.
[0027] There is a need for stable and bioavailable pharmaceutical granule compositions of Banzakafter, Tezakafter, and Dutivakafter that enable accurate and flexible dosing in pediatric patients aged 12 to 24 months and 2 to 5 years by changing the number of granules in a unit dose, packet, pouch, or capsule.
[0028] The present invention relates to a pharmaceutical granule composition comprising Banja-kafter, Teja-kafter, and Dutiva-kafter, and a method for preparing and administering the pharmaceutical composition comprising Banja-kafter, Teja-kafter, and Dutiva-kafter. The pharmaceutical granule composition comprising Banja-kafter, Teja-kafter, and Dutiva-kafter may also comprise one or more excipients selected from one or more fillers, sweeteners, disintegrants, wetting agents, lubricants, and lubricants.
[0029] The pharmaceutical granule compositions disclosed herein have been found to be reproducible and to enable the accurate administration of Banzakafter to pediatric patients in unit doses of about 12 mg or less (e.g., unit doses of about 1 mg, about 2 mg, about 4 mg, about 6 mg, about 8 mg, about 10 mg, or about 12 mg) while maintaining desirable levels of palatability and ease of administration. The pharmaceutical granule compositions disclosed herein have also been found to possess beneficial properties such as improved dispersibility, physical and chemical stability, and a high level of bioavailability.
[0030] The pharmaceutical composition of the present invention is formulated into a plurality of granules. The granules may be contained in capsules, pouches, packets, sachets, bottles, or blister packs to provide a unit dosage form. The granules may also be compressed into other solid forms such as pellets, beads, particles, microparticles, troches, or other equivalent dosage forms. In one embodiment, the pharmaceutical granule composition described herein comprises (a) a solid dispersion containing crystalline banzakafter calcium salt hydrate form D, tezakafter, and a solid dispersion containing dutybakafter, and (b) one or more pharmaceutically acceptable excipients (e.g., one or more fillers, sweeteners, disintegrants, optionally wetting agents, lubricants, and lubricants), wherein a plurality of granules are contained within a unit dosage form, and the unit dosage form also contains a unit dose, i.e., a specified amount, of banzakafter calcium salt hydrate form D in the range of at least about 1 mg to at least about 12.7 mg per unit dosage form, amorphous tezakafter in the range of about 10 mg to about 50 mg per unit dosage form, and amorphous dutybakafter in the range of about 15 mg to about 150 mg per unit dosage form.
[0031] In one embodiment, the present invention relates to a unit dosage form of a pharmaceutical composition comprising a plurality of granules formulated to deliver a crystalline banzakafter calcium salt hydrate form D of about 0.1 mg to about 12.7 mg (e.g., about 1 mg, about 2.1 mg, about 3 mg, about 4.2 mg, about 6 mg, about 6.4 mg, about 8 mg, about 8.5 mg, about 10 mg, about 10.6 mg, or about 12.7 mg), a solid dispersion comprising amorphous tezakafter of about 10 mg to about 50 mg (e.g., about 10 mg, about 16 mg, about 24 mg, about 32 mg, or about 48 mg), and a solid dispersion comprising amorphous dutybakafter of about 40 mg to about 150 mg (e.g., about 50 mg, about 75 mg, about 100 mg, or about 150 mg). The present invention provides. In certain embodiments, the present invention provides a pharmaceutical composition formulated to deliver a unit dosage form comprising about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of amorphous tezakafter, and about 50 mg of amorphous dutybacarfter. In certain embodiments, the present invention provides a pharmaceutical composition formulated to deliver a unit dosage form comprising about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutybacarfter. In certain embodiments, the present invention provides a pharmaceutical composition formulated to deliver a unit dosage form comprising about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of amorphous tezakafter, and about 100 mg of amorphous dutybacarfter. In a specific embodiment, the present invention provides a pharmaceutical composition formulated to deliver a unit dosage form comprising about 12.7 mg of crystalline banzacafter calcium salt hydrate form D, about 48 mg of amorphous tezacafter, and about 150 mg of amorphous dutivacafter.
[0032] In some embodiments, the pharmaceutical granule composition disclosed herein comprises a first solid dispersion comprising tejacarfter and a second solid dispersion comprising dutybacarfter. In some embodiments, one or both of the solid dispersions are spray-drying dispersions. In some embodiments, the solid dispersions and spray-drying dispersions of the disclosure may comprise excipients, such as polymers and / or surfactants.
[0033] In some embodiments, sodium lauryl sulfate (SLS) is used as a surfactant in the solid dispersion of the duty barcarfter. The amount of surfactant (e.g., SLS) relative to the total weight of the solid dispersion may be from 0.1% w / w to 15% w / w. For example, this is from 0.5% w / w to 10% w / w, e.g., from 0.5% w / w to 5% w / w, e.g., from 0.5% w / w to 4% w / w, from 0.5% w / w to 3% w / w, from 0.5% w / w to 2% w / w, from 0.5% w / w to 1% w / w, or 0.5% w / w. In certain embodiments, the amount of surfactant relative to the total weight of the solid dispersion is at least 0.1% w / w or at least 0.5% w / w. The amount of surfactant (e.g., SLS) relative to the total weight of the solid dispersion may also be about 0.1% w / w to about 15% w / w. For example, this is about 0.5% w / w to about 10% w / w, e.g., about 0.5% w / w to about 5% w / w, e.g., about 0.5% w / w to about 4% w / w, about 0.5% w / w to about 3% w / w, about 0.5% w / w to about 2% w / w, about 0.5% w / w to about 1% w / w, or about 0.5% w / w. In certain embodiments, the amount of surfactant relative to the total weight of the solid dispersion is at least about 0.1% w / w or at least about 0.5% w / w. In some embodiments, the surfactant is SLS. In some embodiments, the solid dispersion of the duty barcarfter contains about 0.5% SLS by weight of the solid dispersion of the duty barcarfter.
[0034] In some embodiments, the tejakafter or dutybakafter is present in an amount exceeding half the weight percentage of the dispersion. In some embodiments, the first solid dispersion comprises about 70 wt% to about 90 wt% (e.g., about 75 wt% to about 85 wt%) of tejakafter. In some embodiments, the second solid dispersion comprises about 70 wt% to about 90 wt% (e.g., about 75 wt% to about 85 wt%) of dutybakafter. For example, in some embodiments, in a solid dispersion containing tejakafter, the polymer is present in about 20 wt% based on the weight of the solid dispersion, and the amorphous tejakafter is present in about 80 wt% based on the weight of the solid dispersion.
[0035] In one embodiment, the solid dispersion of tezakarfter comprises about 80 wt% of amorphous tezakarfter based on the weight of the solid dispersion and about 20 wt% of HPMC based on the weight of the solid dispersion.
[0036] In one embodiment, the solid dispersion of the duty barcarfter comprises about 80 wt% of amorphous duty barcarfter based on the weight of the solid dispersion, about 19.5 wt% of HPMCAS based on the weight of the solid dispersion, and about 0.5 wt% of SLS based on the weight of the dispersion.
[0037] In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of 5 to 100 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of 15 to 40 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of 15 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of about 5 to about 100 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of about 15 to about 40 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of about 15 microns.
[0038] In another additional embodiment, in addition to the active pharmaceutical agent (API), the pharmaceutical composition disclosed herein comprises one or more fillers (e.g., mannitol, cellulose, calcium carbonate, starch, sugars (e.g., dextrose, lactose, etc.)) at a concentration of at least about 10 wt% (e.g., about 10 to about 50 wt%, about 20 to about 60 wt%, about 30 to about 70 wt%) based on the weight of the composition; and a sweetener (e.g., sucralose, sorbitol, saccharin, fructose, aspartame, or a combination thereof) at a concentration of about 10 wt% or less (e.g., about 0 to about 10 wt%, about 0 to about 5 wt%, about 0 to about 3 wt%) based on the weight of the composition; A disintegrant at a concentration of about 10 wt% or less (e.g., about 0 to about 10 wt%, about 0 to about 8 wt%, about 0 to about 6 wt%) based on the weight of the composition (e.g., sodium croscarmellose, sodium starch glycolic acid, or a combination thereof); optionally, a wetting agent at a concentration of about 10 wt% or less (e.g., about 0 to about 10 wt%, about 0 to about 5 wt%, about 0 to about 2 wt%) based on the weight of the composition (e.g., sodium lauryl sulfate, SLS); a lubricant at a concentration of about 3 wt% or less (e.g., about 0 to about 3 wt%, about 0 to about 2 wt%, about 0 to about 1 wt%) based on the weight of the composition (e.g., colloidal silicon dioxide, talc, or a combination thereof); and also includes a lubricant (e.g., magnesium stearate, stearic acid, hydrogenated oil, sodium stearyl fumarate, or any combination thereof) at a concentration of about 3 wt% or less (e.g., about 0 to about 3 wt%, about 0 to about 2 wt%, about 0 to about 1 wt%) based on the weight of the composition.
[0039] These pharmaceutical compositions may optionally include one or more coloring agents, flavorings, and / or flavoring agents to enhance their visual appeal, taste, and aroma.
[0040] In one embodiment, the present invention comprises a pharmaceutical composition comprising a crystalline banjacarfter calcium salt hydrate form D, a first solid dispersion comprising amorphous tejacarfter, a second solid dispersion comprising amorphous dutybacarfter, one or more fillers, a sweetener, a disintegrant, a lubricant and a lubricant, and optionally a wetting agent.
[0041] In some embodiments, the filler comprises mannitol present in an amount of about 10 to about 45 percent by weight of the composition. In some embodiments, the filler comprises lactose present in an amount of about 25 to about 45 percent by weight of the composition. In some embodiments, the filler is a binary comprising both mannitol and lactose. In some embodiments, the binary filler comprises mannitol present in an amount of about 10 to about 45 percent by weight of the composition (e.g., about 10 to about 15 percent, about 11 to about 13 percent, about 12 percent, about 12.5 percent), and lactose present in an amount of about 25 to about 45 percent by weight of the composition (e.g., about 30 to about 40 percent, about 34 to about 38 percent, about 35 percent, about 35.5 percent, about 36 percent). In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to 5. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to 4. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to 3. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to 2. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to 1.5. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to about 5. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to about 4. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to about 3. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to about 2. In some embodiments, the binary filler comprises mannitol to lactose in a weight ratio of about 1 to about 1.5.
[0042] In one embodiment, the sweetener comprises sucralose present in an amount of about 0.1 to about 5 percent (e.g., about 1 to about 4 percent, about 2 to about 3 percent, about 2 percent, about 2.2 percent, about 2.3 percent, about 2.4 percent) based on the weight of the composition.
[0043] In one embodiment, the disintegrant comprises sodium croscarmellose present in an amount of about 1 to about 8 percent (e.g., about 2 to about 7.5 percent, about 3.5 to about 7 percent, about 5 to about 6.5 percent) based on the weight of the composition.
[0044] In one embodiment, the wetting agent comprises sodium lauryl sulfate present in an amount of about 2 percent or less (e.g., about 0 to about 2 percent, about 0 to about 1 percent) based on the weight of the composition.
[0045] In one embodiment, the lubricant comprises talc, colloidal silica (i.e., colloidal silicon dioxide), precipitated silica, magnesium oxide, magnesium silicate, leucine, and starch. In a further embodiment, the lubricant comprises colloidal silica present in an amount of about 0.1 to about 5 percent (e.g., about 0.1 to about 4 percent, about 0.5 to about 3 percent, about 0.5 percent, about 1 percent, about 1.5 percent) based on the weight of the composition.
[0046] In one embodiment, the lubricant comprises magnesium stearate present in an amount of about 0.5 to about 2.0 percent (e.g., about 0.75 to about 1.25 percent, about 0.5 to about 1.5 percent, about 0.5 percent, about 1 percent, about 1.5 percent, about 2 percent) based on the weight of the composition.
[0047] The present invention considers stable solid dosage forms, such as granules, that overcome the problems described above, particularly in relation to dosage inaccuracies in pediatric patients. These stable solid unit dosage forms may have any shape, including, in particular, elliptical, spherical, cylindrical, ellipsoidal, cubic, square, or rectangular. The granules may have flat, shallow, standard, deep convex surfaces, or double deep convex surfaces, or a combination thereof.
[0048] In one embodiment, the pharmaceutical granule composition may be formulated into a unit dosage form containing at least one granule, e.g., a capsule, a sachet, etc., to simplify administration of the pharmaceutical composition. In some embodiments, the unit dosage form may include a capsule or a packet containing at least one granule, or a plurality of granules. In another embodiment, the unit dose may include a pouch, a packet, or a sachet containing a specific dose of a solid dispersion containing a solid dispersion containing a crystalline banjacafter calcium salt hydrate form D, an amorphous tejacafter, and a dutivacafter.
[0049] The pharmaceutical composition as described herein may be in the form of a plurality of granules comprising any number of granules (e.g., at least 10, at least 20, at least 40, at least 60, at least 80, at least 90, at least 100, or any number greater than 100; at least about 10, at least about 20, at least about 40, at least about 60, at least about 80, at least about 90, at least about 100, or any number greater than about 100, including all ranges in between). In one embodiment, the plurality of granules contains about 20 to about 40 granules (e.g., about 25, about 30, about 35). In one embodiment, the plurality of granules contains 30 granules. In one embodiment, the plurality of granules contains about 30 granules. Accordingly, the pharmaceutical composition as described herein may be in the form of individual granules or a plurality of granules.
[0050] In one embodiment, the plurality of granules contains 30 granules, wherein the plurality of granules contains a unit dose of 4 mg of banzakafter. In one embodiment, the plurality of granules contains 45 granules, wherein the plurality of granules contains a unit dose of 6 mg of banzakafter. In one embodiment, the plurality of granules contains 60 granules, wherein the plurality of granules contain a unit dose of 8 mg of banzakafter. In one embodiment, the plurality of granules contains 90 granules, wherein the plurality of granules contain a unit dose of 12 mg of banzakafter. In one embodiment, the plurality of granules contains about 30 granules, wherein the plurality of granules contain a unit dose of about 4 mg of banzakafter. In one embodiment, the plurality of granules contains about 45 granules, wherein the plurality of granules contains a unit dose of about 6 mg of banzakafter. In one embodiment, the plurality of granules contains about 60 granules, wherein the plurality of granules contains a unit dose of about 8 mg of banzakafter. In one embodiment, the plurality of granules contains about 90 granules, wherein the plurality of granules contain a unit dose of about 12 mg of banzakafter.
[0051] In another embodiment, the granules described herein are colored by means of incorporating a coloring agent into the granule formulation or by coloring the surface of the granules.
[0052] In other embodiments, a pharmaceutical composition comprising a plurality of granules may be in a pouch, sachet, packet, bottle, or blister pack, or may optionally be further compressed into different solid unit dose forms that can be easily administered to patients who have difficulty swallowing adult-sized tablet formulations. Thus, these novel pharmaceutical compositions and unit dose forms containing said pharmaceutical compositions may be sensorially acceptable to said patients and may be administered to patients who have difficulty swallowing adult tablets by being sprinkled onto liquids or soft foods to ensure that the entire prescribed dose is dissolved or dispersed within various liquids and soft foods or food compositions, such as milk (including breast milk), infant formula or baby food, apple sauce, water, plain yogurt, ice cream, or baby food. Baby food may include, but is not limited to, carrots or carrot puree. The pharmaceutical composition may also be administered into strawberry jam, rice pudding, chocolate pudding, etc. In one embodiment, the unit dose form is administered by being sprinkled onto a soft food. In another embodiment, the unit dose form is administered by being sprinkled onto a liquid. In one embodiment, the unit dose form is sprinkled onto a soft food and mixed to be administered. In another embodiment, the unit dose form is sprinkled onto a liquid and mixed to be administered. The liquid may include, but is not limited to, infant formula, milk, or breast milk. In some cases, for smaller granules, breast milk or formula may be administered after the contents of a packet, pouch, capsule, bottle, or sachet are administered directly to the mouth. The administration method of the present invention may also optionally include the step of administering a liquid or beverage after the contents of a packet, pouch, capsule, bottle, or sachet are administered directly to the mouth, for smaller granules. In some embodiments, any administration method of the present invention may optionally include the step of oral administration with a fat-containing food, such as a standard CF-high-calorie, high-fat meal or snack.In another embodiment, any method of administration of the present invention may optionally include a step of oral administration at the same time, before, or after a fat-containing food, such as a standard CF-high-calorie, high-fat meal or snack. In one embodiment, the pharmaceutical composition of the present invention and its solid unit dose form are particularly useful for the treatment of CFTR-mediated diseases in a population of pediatric patients.
[0053] In one embodiment, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 1 mg to about 12.7 mg of crystalline banzakafter calcium salt hydrate form D. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 4.2 mg of crystalline banzakafter calcium salt hydrate form D. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 8.5 mg of crystalline banzakafter calcium salt hydrate form D. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 12.7 mg of crystalline banzakafter calcium salt hydrate form D.
[0054] In one embodiment, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 10 mg to about 50 mg of amorphous or substantially amorphous tezacafter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 16 mg of amorphous or substantially amorphous tezacafter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 24 mg of amorphous or substantially amorphous tezacafter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 32 mg of amorphous or substantially amorphous tezacafter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 48 mg of amorphous or substantially amorphous tezacafter.
[0055] In one embodiment, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 15 mg to about 150 mg of amorphous or substantially amorphous dutyvacarfter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 50 mg of amorphous or substantially amorphous dutyvacarfter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 75 mg of amorphous or substantially amorphous dutyvacarfter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 100 mg of amorphous or substantially amorphous dutyvacarfter. In some embodiments, the pharmaceutical composition is in a unit dose form comprising a plurality of granules, wherein the unit dose form comprises about 150 mg of amorphous or substantially amorphous dutyvacarfter.
[0056] In another embodiment, solid dispersion(s) comprising tejakafter and dutybakafter are present in the pharmaceutical composition of the present invention in a combined amount of about 20 to about 50 percent by weight of the pharmaceutical composition of the present invention, and the unit dose form is a granule having a shape that is cylindrical, elliptical, conical, spherical, ellipsoidal, polygonal, or a combination thereof, wherein the granule has a longest dimension or diameter of about 1.5 mm to about 4.0 mm.
[0057] In a further embodiment, the combined solid dispersion is present in an amount of about 20 to about 50 percent by weight of the pharmaceutical composition, and the unit volume form is a granule having a shape that is cylindrical, elliptical, conical, spherical, ellipsoidal, polygonal, or a combination thereof, wherein the granule has a longest dimension or diameter of about 2.0 mm.
[0058] In some embodiments, the individual granules weigh about 5.0 mg to about 10 mg. In some embodiments, the individual granules weigh about 6.0 mg to about 9.0 mg. In some embodiments, the individual granules weigh about 6.5 mg to about 8.0 mg. In some embodiments, each granule weighs about 7.0 mg. In some embodiments, each granule has a diameter of about 2.0 mm and weighs about 7.0 mg.
[0059] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising amorphous tezakafter, a solid dispersion comprising amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant to a patient, e.g., a human pediatric patient, once a day, wherein the unit dose comprises about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of substantially amorphous or amorphous tezakafter, and about 50 mg of amorphous or substantially amorphous dutybakafter.
[0060] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising amorphous tezakafter, a solid dispersion comprising amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant to a patient, e.g., a human pediatric patient, once a day, wherein the unit dose comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of substantially amorphous or amorphous tezakafter, and about 75 mg of amorphous or substantially amorphous dutybakafter.
[0061] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising amorphous tezakafter, a solid dispersion comprising amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant to a patient, e.g., a human pediatric patient, once a day, wherein the unit dose comprises about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of substantially amorphous or amorphous tezakafter, and about 100 mg of amorphous or substantially amorphous dutybakafter.
[0062] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising amorphous tezakafter, a solid dispersion comprising amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant to a patient, e.g., a human pediatric patient, once a day, wherein the unit dose comprises about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of substantially amorphous or amorphous tezakafter, and about 150 mg of amorphous or substantially amorphous dutybakafter.
[0063] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering to a patient, e.g., a human pediatric patient, once a day a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising substantially amorphous or amorphous tezakafter, a solid dispersion comprising substantially amorphous or amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant, wherein the unit dose comprises about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of substantially amorphous or amorphous tezakafter, and about 50 mg of amorphous or substantially amorphous dutybakafter.
[0064] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering to a patient, e.g., a human pediatric patient, once a day a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising substantially amorphous or amorphous tezakafter, a solid dispersion comprising substantially amorphous or amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant, wherein the unit dose comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of substantially amorphous or amorphous tezakafter, and about 75 mg of amorphous or substantially amorphous dutybakafter.
[0065] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering to a patient, e.g., a human pediatric patient, once a day a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising substantially amorphous or amorphous tezakafter, a solid dispersion comprising substantially amorphous or amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant, wherein the unit dose comprises about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of substantially amorphous or amorphous tezakafter, and about 100 mg of amorphous or substantially amorphous dutybakafter.
[0066] Another aspect of the present invention provides a method of administering a pharmaceutical composition by orally administering to a patient, e.g., a human pediatric patient, once a day a plurality of granules comprising a crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising substantially amorphous or amorphous tezakafter, a solid dispersion comprising substantially amorphous or amorphous dutybakafter, one or more fillers, a sweetener, a disintegrant, optionally a wetting agent, a lubricant, and a lubricant, wherein the unit dose comprises about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of substantially amorphous or amorphous tezakafter, and about 150 mg of amorphous or substantially amorphous dutybakafter.
[0067] definition
[0068] As used herein, the term “active pharmaceutical ingredient” or “API” refers to a biologically active compound. The API used in the pharmaceutical composition of the present invention is calcium bis((14), which is one of two CF corrector compounds. S )-8-[3-(2-{Disspiro[2.0.2 4 .1 3]heptane-7-yl}ethoxy)pyrazole-1-yl]-12,12-dimethyl-2,2,4-trioxo-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11 , 14 .0 5 , 10 ]tetracosa-1(23),5,7,9,19,21-hexaen-3-ide), (banjacarpter calcium salt) and ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -Indole-5-1)Cyclopropanecarboxamide (Tezacarfter), and CF enhancer, N -(2-( Burst It contains -butyl)-5-hydroxy-4-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Dutivacarfter).
[0069] Banja Kafter
[0070] As used herein, the term "banjacarfter" has the following structure (14 S )-8-[3-(2-{disspiro[2.0.2.1]heptane-7-yl}ethoxy)-1 H -pyrazol-1-yl]-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 ]tetracosa-1(22),5,7,9,19(23),20-hexane-2,2,4-trione is used interchangeably:
[0071]
[0072] As used herein, "banjakafter calcium salt" is calcium bis((14) which is a calcium salt of banjakafter. S )-8-[3-(2-{Disspiro[2.0.2 4 .13 ]heptane-7-yl}ethoxy)pyrazole-1-yl]-12,12-dimethyl-2,2,4-trioxo-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11 , 14 .0 5 , 10 ] refers to tetracosa-1(23),5,7,9,19,21-hexaen-3-id).
[0073] Banzakafter is described in international patent publications WO 2019 / 161078, WO 2020 / 102346, WO 2021 / 030554, WO 2021 / 030552, WO 2022 / 036060, and WO 2022 / 125826, all of which are incorporated herein by reference. These publications also describe a method for manufacturing banzakafter and show that banzakafter is a CFTR corrective therapeutic agent. WO 2021 / 030552 also describes a method for manufacturing banzakafter calcium salt hydrate form D.
[0074] In some embodiments, banjakafter calcium salt hydrate form D is characterized by an X-ray powder diffraction pattern having signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees. In some embodiments, banjakafter calcium salt hydrate form D is (a) signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees; and (b) an X-ray powder diffraction pattern having one or more signals selected from 5.5 ± 0.2 2-theta degrees, 15.5 ± 0.2 2-theta degrees, 19.7 ± 0.2 2-theta degrees, 21.5 ± 0.2 2-theta degrees, 22.1 ± 0.2 2-theta degrees, 23.0 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees.
[0075] In some embodiments, the banjakaftor calcium salt hydrate form D features (a) signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees; and (b) X-ray powder diffraction having two or more signals selected from 5.5 ± 0.2 2-theta degrees, 15.5 ± 0.2 2-theta degrees, 19.7 ± 0.2 2-theta degrees, 21.5 ± 0.2 2-theta degrees, 22.1 ± 0.2 2-theta degrees, 23.0 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees. In some embodiments, the banjakaftor calcium salt hydrate form D is characterized by (a) signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees; and (b) X-ray powder diffraction having three or more signals selected from 5.5 ± 0.2 2-theta degrees, 15.5 ± 0.2 2-theta degrees, 19.7 ± 0.2 2-theta degrees, 21.5 ± 0.2 2-theta degrees, 22.1 ± 0.2 2-theta degrees, 23.0 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees. In some embodiments, the banjakaftor calcium salt hydrate form D features (a) signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees; and (b) an X-ray powder diffraction pattern having four or more signals selected from 5.5 ± 0.2 2-theta degrees, 15.5 ± 0.2 2-theta degrees, 19.7 ± 0.2 2-theta degrees, 21.5 ± 0.2 2-theta degrees, 22.1 ± 0.2 2-theta degrees, 23.0 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees.
[0076] In some embodiments, banjakafter calcium salt hydrate form D is characterized by an X-ray powder diffraction pattern having signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, 22.8 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees. In some embodiments, banjakafter calcium salt hydrate form D is characterized by an X-ray powder diffraction pattern having signals at 6.1 ± 0.2 2-theta degrees, 15.5 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, 19.7 ± 0.2 2-theta degrees, 22.8 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees.
[0077] In some embodiments, the banjakaftor calcium salt hydrate form D features an X-ray powder diffraction pattern substantially similar to that of FIG. 1.
[0078] Tejacarpter
[0079] As used herein, the term "Tejacarfter" ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -Indole-5-il) is used interchangeably with cyclopropanecarboxamide. Tejacarfter can be depicted as having the following structure:
[0080]
[0081] Tejacarfter has been previously described in U.S. Patent Publication US 2009 / 0131492 and international patent publications WO 2011 / 119984 and WO 2015 / 160787, all of which are incorporated herein by reference.
[0082] Duty Vaccart
[0083] As used herein, the term "duty barcarfter" is N -(2-( BurstIt is used interchangeably with -butyl)-5-hydroxy-4-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide. Dutybacarfter has the following structure:
[0084]
[0085] The duty barcarfter has been previously described in international patent publications WO 2012 / 158885, WO 2017 / 053455, WO 2017 / 053711, WO 2018 / 080591, and WO 2019 / 109021, all of which are incorporated herein by reference.
[0086] The terms “about” and “approximately,” when used in relation to the dose, amount, or weight percentage of a component of a composition or dosage form, include a value of a specific dose, amount, or weight percentage, or a range of doses, amounts, or weight percentages recognized by those skilled in the art to provide a pharmacological effect equivalent to that obtained from a specific dose, amount, or weight percentage. The terms “about” and “approximately” may refer to an acceptable error for a specific numerical value (e.g., weight, size, amount, weight percentage, or duration of time) determined by those skilled in the art, depending in part on the method by which the values are measured or determined. In some embodiments, the terms “about” and “approximately” mean within 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, or 0.5% of a given value or range. In some embodiments, the terms “about” and “approximately” mean within 10% of a given value or range. In some embodiments, the terms “about” and “approximately” mean within 15% of a given value or range. In some embodiments, the terms “about” and “approximately” mean within 20% of a given value or range. In some embodiments, the terms “about” and “approximately” mean within 25% of a given value or range. As used herein, the symbol “~” appearing immediately preceding a number has the same meaning as the terms “about” and “approximately”.
[0087] As used herein, "CFTR" or "CFTR protein" refers to a cystic fibrosis transmembrane conductivity regulator protein.
[0088] As used herein, the term “modifier” refers to a compound that increases the activity of a biological compound, such as a protein. For example, a CFTR modifier is a compound that increases the activity of CFTR. Increases in activity due to a CFTR modifier include, but are not limited to, compounds that correct, enhance, stabilize, and / or amplify CFTR.
[0089] As used herein, “CF enhancer” refers to a compound exhibiting biological activity characterized by increasing the gating function of mutant CFTR proteins present on the cell surface to approximately wild-type levels (i.e., a compound that enhances or induces channel activity of CFTR proteins located on the cell surface, thereby resulting in increased functional activity). The Dutybacarfter disclosed herein is a CFTR enhancer.
[0090] As used herein, the term “CFTR corrector” refers to a compound that enhances or induces the amount of functional CFTR protein on the cell surface, thereby resulting in increased functional activity. Banzakafter and Tezakafter disclosed herein are CFTR correctors.
[0091] The terms "patient" and "subject" are used interchangeably and refer to animals, including humans.
[0092] As used herein, terms such as “treatment,” “treating,” “treating,” etc. generally mean improvement of CF or its symptoms in a subject or reduction of the severity of CF or one or more of its symptoms. “Treatment,” as used herein, includes, but is not limited to: increased growth of the subject, increased weight gain, reduced mucus in the lungs, improved pancreatic and / or liver function, reduction of chest infection, and / or reduction of cough or dyspnea. Any improvement or reduction in the severity of any of these symptoms may be readily evaluated according to standard methods and techniques known in the art.
[0093] As used herein, when referring to two or more compounds, formulations, or additional active pharmaceutical ingredients, the term “in combination with” means administering two or more compounds, formulations, or active pharmaceutical ingredients to a patient prior to, simultaneously with, or subsequently to each other.
[0094] As used herein, the term “amorphous” refers to a solid material that does not possess long-range order at the positions of its molecules. An amorphous solid is generally a supercooled liquid in which molecules are arranged randomly without a clearly defined arrangement, e.g., molecular packing and long-range order. Amorphous solids are generally isotropic, meaning they exhibit similar properties in all directions and do not have a distinct melting point. For example, an amorphous material is a solid material that does not possess distinct characteristic crystalline peak(s) in an X-ray powder diffraction (XRPD) pattern (i.e., is not crystalline as determined by XRPD). Instead, one or more broad peaks (e.g., halos) appear in its XRPD pattern. Broad peaks are a characteristic of amorphous solids. For a comparison of XRPDs of amorphous and crystalline materials, see US 2004 / 0006237. reference .... In some embodiments, the solid material may comprise an amorphous compound, and the material may be characterized, for example, by the absence of distinct characteristic crystalline peak(s) in its XRPD spectrum (i.e., the material is amorphous, not crystalline as determined by XRPD). Instead, one or several broad peaks (e.g., halos) may appear in the XRPD pattern of the material. For a comparison of the XRPDs of amorphous and crystalline materials, see US 2004 / 0006237 reference Solid materials containing amorphous compounds can be characterized by a wider temperature range for melting compared to, for example, the range for melting of pure crystalline solids. For example, other techniques such as Raman spectroscopy, infrared spectroscopy, and solid-state NMR can be used to characterize crystalline or amorphous forms.
[0095] In some embodiments, the solid material may comprise a mixture of crystalline solids and amorphous solids. A solid material prepared to comprise an amorphous compound may also, for example, contain up to about 30% of crystalline solids. A solid material prepared to comprise an amorphous compound may also, for example, contain up to 30% of crystalline solids. In some embodiments, a solid material prepared to comprise an amorphous compound may also, for example, contain up to 25%, 20%, 15%, 10%, 5%, 2%, about 25%, about 20%, about 15%, about 10%, about 5%, or about 2% of crystalline solids. In embodiments where the solid material comprises a mixture of crystalline solids and amorphous solids, characterization data such as XRPD may contain indicators of both crystalline and amorphous solids.
[0096] As used herein, the term “substantially amorphous” refers to a solid material that has little to no long-range order at its molecular positions. For example, a substantially amorphous material has a degree of crystallization of less than about 15% (e.g., less than about 10% or less than about 5%). It is also noted that the term “substantially amorphous” includes the descriptive term “amorphous,” which refers to a material that has no degree of crystallization (0%).
[0097] As used herein, the term “dispersion” refers to a dispersion system in which a dispersed phase, which is a single substance, is distributed as distinct units throughout a second substance (continuous phase or vehicle). The size of the dispersed phase can vary considerably (e.g., from a single molecule, nanometer-sized colloidal particle to a size of several microns). Generally, the dispersed phase can be a solid, a liquid, or a gas. In the case of a solid dispersion, both the dispersed phase and the continuous phase are solid. In the present invention, the solid dispersion may comprise an amorphous drug within an amorphous polymer or an amorphous drug within a crystalline polymer. In some embodiments, the solid dispersion comprises a drug constituting the dispersed phase, and the polymer constitutes the continuous phase.
[0098] As used herein, the term “solid dispersion” generally refers to a solid dispersion of two or more components. In some embodiments, the solid dispersion comprises a single API (e.g., tezakarfter or dutyvakarfter). In some embodiments, the solid dispersion comprises two APIs (e.g., tezakarfter and dutyvakarfter). In some embodiments, the solid dispersion contains a polymer, but may contain other components, such as a surfactant or other pharmaceutical excipients, wherein the drug(s) (e.g., tezakarfter and / or dutyvakarfter) are substantially amorphous (e.g., about 15% or less (e.g., about 10% or less, or about 5% or less)) crystalline drugs or amorphous (i.e., not containing crystalline drugs), and the physical stability and / or dissolution and / or solubility of the substantially amorphous or amorphous drugs are enhanced by the other components. The solid dispersion typically comprises a compound dispersed in a suitable carrier medium, such as a solid-state carrier. For example, the carrier may comprise a polymer (e.g., a water-soluble polymer or a partially water-soluble polymer) and optional excipients, such as functional excipients (e.g., one or more surfactants) or non-functional excipients (e.g., one or more fillers). Another exemplary solid dispersion is a co-precipitate or co-melt of Tejakafter and / or Dutivakafter, optionally comprising at least one polymer.
[0099] As used herein, "degree of crystallization" refers to the degree of structural order within a solid. For example, a substantially amorphous material has a degree of crystallization of less than about 15%, or its solid-state structure has a degree of crystallization of less than about 15%. In another example, a completely amorphous material has a degree of crystallization of zero (0%).
[0100] As used herein, the terms “X-ray powder diffraction,” “X-ray powder diffraction pattern,” “XRPD pattern,” and “XRPD spectrum” refer interchangeably to an experimentally obtained pattern plotting signal position (on the horizontal coordinate) versus signal intensity (on the vertical coordinate). For amorphous materials, the X-ray powder diffraction may contain one or more broad signals; for crystalline materials, the X-ray powder diffraction may contain one or more signals, each of which is identified by its angular value as measured as 2θ (° 2θ) on the horizontal coordinate of the X-ray powder diffraction, which may be expressed as “...signal at 2-theta degrees,” “signal at 2-theta value(s) of,” and / or “signal at at least ... 2-theta value(s) selected from.”
[0101] As used herein, “signal” or “peak” refers to a point in an XRPD pattern where the intensity measured by count is at a national baseline. Those skilled in the art will recognize that one or more signals (or peaks) in an XRPD pattern may overlap and, for example, may not be clearly visible to the naked eye. In practice, those skilled in the art will recognize that methods recognized in some technical fields can determine whether signals exist in a pattern such as Rietveld precision and are suitable.
[0102] As used herein, "...signal at 2-theta degrees" refers to the X-ray reflection position measured and observed in X-ray powder diffraction experiments (° 2θ).
[0103] The repeatability of the measured angle value is within the range of ± 0.2° 2θ, that is, the angle value can be the quoted angle value + 0.2 2-theta degrees, the angle value -0.2 2-theta degrees, or any value between these two end points (angle value + 0.2 2-theta degrees and angle value -0.2 2-theta degrees).
[0104] As used herein, the term “granule” refers to a solid particulate pharmaceutical composition suitable for administration to patients who have difficulty swallowing large tablets or capsules, e.g., pediatric patients. As used herein, “granule” is equivalent to similar terms such as mini-tablets, sprinkles, pellets, beads, particles, particulates, and troches, many of which may be contained in capsules, pouches, packets, sachets, bottles, or blister packs to provide unit dosage forms.
[0105] As used herein, “unit dose form” and “unit dosage form” are used interchangeably to refer to a package containing a plurality of granules (e.g., capsule, packet, sachet, or pouch), and the solid dose form contains a specific amount (i.e., unit dose) of API (e.g., banzacarfter, tezacarfter, and / or dutivacarfter) per dose.
[0106] As used herein, "excipients" are inactive components in a pharmaceutical composition. Examples of excipients include fillers, sweeteners, disintegrants, lubricants, lubricants, etc.
[0107] As used herein, "diluent" or "filler" is an excipient that adds bulkiness to a pharmaceutical composition. Examples of fillers include mannitol, lactose, cellulose, such as microcrystalline cellulose and ethyl cellulose, cellulose acetate, calcium carbonate, potato starch, sorbitol, polyhydric alcohols, dextrose, or combinations thereof.
[0108] As used herein, "disintegrant" is an excipient that hydrates a pharmaceutical composition and aids in tablet dispersion. Examples of disintegrants include sodium croscarmellose and / or sodium starch glycolic acid.
[0109] As used herein, "sweetener" is an excipient that imparts sweetness to a pharmaceutical composition and / or masks other unpleasant tastes. Examples of sweeteners include sucralose, sorbitol, xylitol, and combinations thereof.
[0110] As used herein, "lubricant" is an excipient that imparts improved flow properties to a pharmaceutical composition. Examples of lubricants include colloidal silica, precipitated silica, and / or talc.
[0111] As used herein, “colorant” is an excipient that imparts a desired color to a pharmaceutical composition. Examples of colorants include commercially available pigments such as FD&C Blue #1 Aluminum Lake, FD&C Blue #2, other FD&C Blue pigments, titanium dioxide, iron oxide, and / or combinations thereof.
[0112] As used herein, "lubricant" is an excipient added to a pharmaceutical composition to minimize adhesion to a surface, particularly in the case of a pharmaceutical composition that is tableted in granules. The lubricant helps eject the granules of the pharmaceutical composition from the compression die. Examples of lubricants include magnesium stearate, stearic acid (stearin), hydrogenated oil, sodium stearyl fumarate, or any combination thereof.
[0113] As used herein, "average particle diameter" is the average particle diameter measured using techniques such as laser light scattering, image analysis, or sieve analysis.
[0114] As used herein, "bulk density" is the mass of a particle of a material divided by the total volume occupied by the particle. The total volume includes the particle volume, the volume of interparticle voids, and the volume of internal pores. Bulk density is not an intrinsic property of the material and may vary depending on how the material is processed.
[0115] As used herein, “wetting agent” or “surfactant” is an excipient that imparts enhanced solubility and / or wettability to a pharmaceutical composition. Examples of wetting agents include sodium lauryl sulfate (SLS), sodium stearyl fumarate (SSF), polyoxyethylene 20 sorbitan mono-oleate (e.g., Tween™), or any combination thereof.
[0116] Duty Barkapter is deuterium ( 2 It was labeled as H). In the chemical structure, deuterium is represented as "D".
[0117] The concentration of isotope(s) (e.g., deuterium) incorporated into ivacarptor may be defined by an isotope enrichment factor. As used herein, the term "isotope enrichment factor" refers to the ratio between the isotopic abundance and the natural abundance of a particular isotope. In some embodiments, where a substituent in a compound of the present disclosure is referred to as deuterium, such compound has an isotope enrichment factor of at least 3500 (52.5% deuterium incorporation in each specified deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation) for each specified deuterium atom. Specific details for implementing the invention
[0118] The present invention relates to calcium bis((14 S )-8-[3-(2-{Disspiro[2.0.2 4 .1 3 ]heptane-7-yl}ethoxy)pyrazole-1-yl]-12,12-dimethyl-2,2,4-trioxo-2λ 6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11 , 14 .0 5 , 10 ]tetracosa-1(23),5,7,9,19,21-hexaen-3-ide) (banjacarfter calcium salt), ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -Indole-5-il)cyclopropanecarboxamide (Tezacarfter), and N -(2-( Burst The invention relates to a pharmaceutical composition containing (-butyl)-5-hydroxy-4-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Dutivacafter), comprising a granular formulation of the solid composition, a method for manufacturing and processing the granules, and a method for treating cystic fibrosis using the pharmaceutical composition. In some embodiments, the banzacafter calcium salt is a crystalline banzacafter calcium salt hydrate form D. In some embodiments, the tezacafter is an amorphous tezacafter in a solid dispersion. In some embodiments, the dutybacafter is an amorphous tezacafter in a solid dispersion.
[0119] solid dispersion
[0120] In some embodiments, the pharmaceutical composition disclosed herein comprises a first solid dispersion comprising an amorphous tejacarfter and a second solid dispersion comprising an amorphous dutyvacarfter. In some embodiments, one or both of the solid dispersions are spray-drying dispersions.
[0121] In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of 5 to 100 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of 15 to 40 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of 15 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of about 5 to about 100 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of about 15 to about 40 microns. In some embodiments, the first and second solid dispersions each independently comprise a plurality of particles having an average particle diameter of about 15 microns.
[0122] In some embodiments, the solid dispersions and spray-dried dispersions of the present disclosure may include other excipients, such as polymers and / or surfactants. Any suitable polymer and surfactant known in the art may be used. Certain exemplary polymers and surfactants are as described below.
[0123] Solid dispersions of amorphous tejakafter and / or amorphous dutybakafter may be prepared by any suitable method known in the art, e.g., spray drying, freeze-drying, hot melting, or cryogenic grinding / cryogenic milling techniques. Typically, these spray drying, freeze-drying, hot melting, or cryogenic grinding / cryogenic milling techniques produce amorphous forms of APIs (e.g., tejakafter and dutybakafter).
[0124] Spray drying is a process that converts a liquid feed into a dried particulate form. Optionally, secondary drying processes, such as fluidized bed drying or vacuum drying, may be used to reduce residual solvent to pharmaceutically acceptable levels. Typically, spray drying involves contacting a highly dispersed liquid suspension or solution with a volume of high-temperature gas sufficient to cause the evaporation and drying of liquid droplets. The formulation to be spray dried can be any solution, coarse suspension, slurry, colloidal dispersion, or paste that can be atomized using a selected spray drying device. In one procedure, the formulation is sprayed into a stream of warm, filtered gas that evaporates the solvent and transports the dried product to a collector (e.g., a cyclone). The used gas is then exhausted along with the solvent, or alternatively, the used air is sent to a condenser to capture the solvent and potentially recycle it. Commercially available types of devices may be used to perform spray drying. For example, commercial spray dryers are available from Buchi Ltd. and is manufactured by Niro (e.g., PSD line spray dryer manufactured by Niro) (US 2004 / 0105820; US 2003 / 0144257 reference ).
[0125] Techniques and methods for spray drying can be found in Perry's Chemical Engineering Handbook, 6th Ed., RH Perry, DW Green & JO Maloney, eds., McGraw-Hill book co. (1984); and Marshall, "Atomization and Spray-Drying," 50, Chem. Eng. Prog. Monogr. Series 2 (1954).
[0126] The removal of the solvent may require subsequent drying steps such as tray drying, fluid bed drying, vacuum drying, microwave drying, rotary drum drying, or biconical vacuum drying. In one embodiment, the solid dispersion and spray-dried dispersion of the present disclosure are fluid bed dried. In one process, the solvent comprises a volatile solvent, for example, a solvent having a boiling point of less than 100°C. In some embodiments, the solvent comprises a mixture of solvents, for example, a mixture of volatile solvents or a mixture of volatile and non-volatile solvents. When a mixture of solvents is used, the mixture may comprise one or more non-volatile solvents, for example, wherein the non-volatile solvent is present in the mixture in an amount of less than 15%, e.g., less than 12%, less than 10%, less than 8%, less than 5%, less than 3%, or less than 2%. When a mixture of solvents is used, the mixture may also contain one or more non-volatile solvents, for example, where the non-volatile solvent is present in the mixture in an amount of less than about 15%, for example, less than about 12%, less than about 10%, less than about 8%, less than about 5%, less than about 3%, or less than about 2%.
[0127] Optimal solid dispersions can be prepared by varying the particle size and drying temperature range. As recognized by those skilled in the art, smaller particle sizes will lead to improved solvent removal. However, smaller particles can result in lower bulk density, which has been found to fail to provide an optimal solid dispersion for downstream processes in some situations.
[0128] The solid dispersions disclosed herein (e.g., spray-dried dispersions) may optionally include a surfactant. The surfactant or a mixture of surfactants will generally reduce the interfacial tension between the solid dispersion and the aqueous medium. A suitable surfactant or a mixture of surfactants may also improve the water solubility and bioavailability of API(s) (e.g., amorphous tejacarfter and / or amorphous dutybacarfter) from the solid dispersion. Surfactants for use in connection with the present disclosure include sorbitan fatty acid esters (e.g., Spans®), polyoxyethylene sorbitan fatty acid esters (e.g., Tweens®), sodium lauryl sulfate (SLS), sodium dodecylbenzene sulfonate (SDBS), dioctyl sodium sulfosuccinate (sodium docusate), sodium deoxycholate salt (DOSS), sorbitan monostearate, sorbitan tristearate, hexadecyltrimethylammonium bromide (HTAB), sodium N-lauroylsarcosine, sodium oleate, sodium myristate, sodium stearate, sodium palmitate, Gelucire 44 / 14, ethylenediaminetetraacetic acid (EDTA), vitamin E d-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS), lecithin, monosodium glutamate monohydrate, labrasol, and PEG 8 Caprylic / capric glycerides, transcutol, diethylene glycol monoethyl ether, Solutol HS-15, polyethylene glycol / hydroxystearate, taurocholic acid, Pluronic F68, Pluronic F108, and Pluronic F127 (or any other polyoxyethylene-polyoxypropylene copolymer (Pluronics®) or saturated polyglycolated glycerides (Gelucirs®)), but not limited thereto.Specific examples of such surfactants that may be used in connection with the present disclosure include, but are not limited to, Span 65, Span 25, Tween 20, Capryol 90, Pluronic F108, sodium lauryl sulfate (SLS), vitamin E TPGS, Pluronic series, and copolymers.
[0129] In some embodiments, SLS is used as a surfactant in a solid dispersion of amorphous duty barcarfter. The amount of surfactant (e.g., SLS) relative to the total weight of the solid dispersion may be from 0.1% w / w to 15% w / w. For example, this is from 0.5% w / w to 10% w / w, e.g., from 0.5% w / w to 5% w / w, e.g., from 0.5% w / w to 4% w / w, from 0.5% w / w to 3% w / w, from 0.5% w / w to 2% w / w, from 0.5% w / w to 1% w / w, or 0.5% w / w. In certain embodiments, the amount of surfactant relative to the total weight of the solid dispersion is at least 0.1% w / w or at least 0.5% w / w. In some embodiments, the surfactant is an amount of SLS of 0.5% by weight. The amount of surfactant (e.g., SLS) relative to the total weight of the solid dispersion may also be about 0.1% w / w to about 15% w / w. For example, this is about 0.5% w / w to about 10% w / w, e.g., about 0.5% w / w to about 5% w / w, e.g., about 0.5% w / w to about 4% w / w, about 0.5% w / w to about 3% w / w, about 0.5% w / w to about 2% w / w, about 0.5% w / w to about 1% w / w, or about 0.5% w / w. In certain embodiments, the amount of surfactant relative to the total weight of the solid dispersion is at least about 0.1% w / w or at least about 0.5% w / w. In some embodiments, the surfactant is about 0.5% by weight of SLS.
[0130] Another aspect of the present disclosure provides a single spray-dried dispersion comprising an amorphous tejakafter and an amorphous dutybakafter, wherein the dispersion is prepared without a polymer, and wherein the spray-dried dispersion is produced by the steps of: (i) providing a mixture essentially consisting of an amorphous tejakafter and an amorphous dutybakafter and a solvent; and (ii) forcing the mixture through a nozzle under spray-drying conditions to produce a spray-dried dispersion.
[0131] In some embodiments, solid dispersions for inclusion in the pharmaceutically acceptable compositions of the present disclosure may be prepared by non-spray drying techniques, e.g., cryogenic grinding / cryogenic milling techniques. Solid dispersions comprising amorphous tejacarfter or amorphous dutybacarfter may also be prepared by hot melt extrusion techniques.
[0132] In some embodiments, the solid dispersion of the present disclosure (e.g., spray-dried dispersion) comprises polymer(s). Any suitable polymer known in the art may be used in the present disclosure. Exemplary suitable polymers include polymers selected from cellulose-based polymers, polyoxyethylene-based polymers, polyethylene-propylene glycol copolymers, vinyl-based polymers, PEO-polyvinyl caprolactam-based polymers, and polymethacrylate-based polymers.
[0133] Cellulose-based polymers include methylcellulose, hydroxypropyl methylcellulose (HPMC) (hypromellose), hypromellose phthalate (HPMC-P), hypromellose acetate succinate, and copolymers thereof. Polyoxyethylene-based polymers include polyethylene-propylene glycol, polyethylene glycol, poloxamer, and copolymers thereof. Vinyl-based polymers include polyvinylpyrrolidine (PVP) and PVP / VA. PEO-polyvinyl caprolactam-based polymers include polyethylene glycol, polyvinyl acetate, and polyvinyl caprolactam-based graft copolymers (e.g., Soluplus®). Polymethacrylate-based polymers are synthetic cationic and anionic polymers of dimethylaminoethyl methacrylate, methacrylic acid, and methacrylic acid esters in various proportions. Several types are commercially available and can be obtained as dry powder, aqueous dispersion, or organic solution. Examples of such polymethacrylate-based polymers include poly(methacrylic acid, ethyl acrylate) (1:1), dimethylaminoethyl methacrylate-methyl methacrylate copolymer, and Eudragit®.
[0134] In some embodiments, the cellulose-based polymer is hypromellose acetate succinate (also known as hydroxypropyl methylcellulose acetate succinate or HMPCAS) and hypromellose (also known as hydroxypropyl methylcellulose or HPMC), or a combination of hypromellose acetate succinate and hypromellose. HPMCAS is available in various grades depending on the content (wt%) of acetyl and succinoyl groups within the HPMCAS molecule and the particle size. For example, HPMCAS grades L, M, and H are available. HPMCAS-H is a grade containing about 10–14 wt% acetyl groups and about 4–8 wt% succinoyl groups. Each HPMCAS grade is available in two particle sizes, F (fine) and G (granular). HPMC is provided in various types (e.g., HPMC E, F, J, and K-types). HPMC E type means that there are approximately 28-30% methoxy groups and approximately 7-12% hydroxypropoxy groups. There are various E grades ranging from low to high viscosity. For example, E3 means that the viscosity of HPMC measured at 2% in water at 20°C is approximately 2.4-3.6 millipascal-seconds (mPa·s); E15 means that the viscosity of HPMC measured at 2% in water at 20°C is approximately 12-18 mPa·s; and E50 means that the viscosity of HPMC measured at 2% in water at 20°C is approximately 40-60 mPa·s.
[0135] In some embodiments, the cellulose-based polymer is hypromellose acetate succinate and hypromellose, or a combination of hypromellose acetate succinate and hypromellose. In some embodiments, the cellulose-based polymer is hypromellose E15, hypromellose acetate succinate L, or hypromellose acetate succinate H. In some embodiments, the polyoxyethylene-based polymer or polyethylene-propylene glycol copolymer is polyethylene glycol or Pluronic. In some embodiments, the polyoxyethylene-based polymer or polyethylene-propylene glycol copolymer is polyethylene glycol 3350 or poloxamer 407. In some embodiments, the vinyl-based polymer is a vinylpolyvinylpyrrolidine-based polymer, such as polyvinylpyrrolidine K30 or polyvinylpyrrolidine VA 64. In some embodiments, the polymethacrylate polymer is Eudragit® L100-55 or Eudragit® E PO. In some embodiments, the polymer(s) are selected from cellulose polymers, such as HPMC and / or HPMCAS.
[0136] In one embodiment, the polymer may be soluble in an aqueous medium. The solubility of the polymer may be pH-independent or pH-dependent. The latter comprises one or more enteric polymers. The term "enteric polymer" refers to a polymer that dissolves preferentially in the less acidic environment of the intestine compared to the more acidic environment above, for example, a polymer that is insoluble in an acidic aqueous medium but dissolves when the pH exceeds 5-6. Suitable polymers are chemically and biologically inert. To improve the physical stability of the solid dispersion, the glass transition temperature (T) of the polymer g ) is as high as possible. For example, it is a polymer whose glass transition temperature is at least equal to or higher than the glass transition temperature of the API. Other polymers have glass transition temperatures that differ from the glass transition temperature of the API within about 10°C to about 15°C.
[0137] In addition, the hygroscopicity of the polymer is low, for example, less than about 10%. For comparative purposes in this application, the hygroscopicity of the polymer or composition is characterized at about 60% relative humidity. In some preferred embodiments, the polymer has a moisture absorption rate of less than 10%, for example, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, or less than 2%. Hygroscopicity can also affect the physical stability of the solid dispersion. Generally, moisture adsorbed to the polymer affects not only the polymer but also the T of the resulting solid dispersion g It can be significantly reduced, which will further reduce the physical stability of the solid dispersion as described above.
[0138] In one embodiment, the polymer is one or more water-soluble polymer(s) or partially water-soluble polymer(s). The water-soluble or partially water-soluble polymers include, but are not limited to, copolymers and derivatives thereof comprising cellulose derivatives (e.g., hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC)) or ethylcellulose; polyvinylpyrrolidone (PVP); polyethylene glycol (PEG); polyvinyl alcohol (PVA); acrylates, such as polymethacrylate (e.g., Eudragit® E); cyclodextrin (e.g., β-cyclodextrin) and, for example, PVP-VA (polyvinylpyrrolidone-vinyl acetate).
[0139] In some embodiments, the polymer is hydroxypropylmethylcellulose (HPMC), such as HPMC E50, HPMC E15, or HPMC E3.
[0140] As discussed herein, the polymer may be a pH-dependent enteric polymer. Such pH-dependent enteric polymers include, but are not limited to, cellulose derivatives (e.g., cellulose acetate phthalate (CAP)), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), carboxymethylcellulose (CMC) or salts thereof (e.g., sodium salts, e.g., (CMC-Na)); cellulose acetate trimellitate (CAT), hydroxypropylcellulose acetate phthalate (HPCAP), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), and methylcellulose acetate phthalate (MCAP), or polymethacrylates (e.g., Eudragit® S). In some embodiments, the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS). In some embodiments, the polymer is hydroxypropyl methylcellulose acetate succinate HG grade (HPMCAS-HG).
[0141] In another embodiment, the polymer is a polyvinylpyrrolidone copolymer, for example, a vinylpyrrolidone / vinyl acetate copolymer (PVP / VA).
[0142] In an embodiment where Tejakafter or Dutivakafter forms a solid dispersion with a polymer, e.g., HPMC, HPMCAS, or PVP / VA polymer, the amount of polymer relative to the total weight of the solid dispersion is in the range of 0.1% to 99% by weight. Unless otherwise specified, the percentages of the drug, polymer, and other excipients as described in the dispersion are provided as weight percentages. The amount of polymer is typically at least 20%, and preferably at least 30%, e.g., at least 35%, at least 40%, at least 45%, or 50% (e.g., 49.5%). The amount is typically 99% or less, and preferably 80% or less, e.g., 75% or less, 70% or less, 65% or less, 60% or less, or 55% or less. In one embodiment, the polymer is present in an amount of up to 50% of the total weight of the dispersion (and more specifically, from 40% to 50%, e.g., 49%, 49.5%, or 50%). In one embodiment, the polymer is present in an amount of up to about 50% of the total weight of the dispersion (and more specifically, from about 40% to about 50%, e.g., about 49%, about 49.5%, or about 50%).
[0143] In some embodiments, tezacafter (or dutyvacafter) and the polymer are present in roughly equal amounts by weight, for example, the polymer and the drug each constitute half of the percentage weight of the dispersion. For example, the polymer is present at 49.5 wt% and the amorphous tezacafter (or amorphous dutyvacafter) is present at 50 wt%. In another embodiment, the amorphous tezacafter (or amorphous dutyvacafter) is present in an amount exceeding half of the weight percentage of the dispersion. In some embodiments, the first solid dispersion comprises 70 wt% to 90 wt% (e.g., 75 wt% to 85 wt%) of amorphous tezacafter. In some embodiments, the second solid dispersion comprises 70 wt% to 90 wt% (e.g., 75 wt% to 85 wt%) of amorphous dutyvacafter. For example, in some embodiments, in a solid dispersion containing tejacafter, the polymer is present at 20 wt% and the amorphous tejacafter is present at 80 wt%. In other embodiments, a solid dispersion of amorphous dutybacafter comprises 19.5 wt% polymer, 80 wt% amorphous dutybacafter, and 0.5 wt% SLS. In some embodiments, the first solid dispersion comprises about 70 wt% to about 90 wt% (e.g., about 75 wt% to about 85 wt%) of amorphous tejacafter. In some embodiments, the second solid dispersion comprises about 70 wt% to about 90 wt% (e.g., about 75 wt% to about 85 wt%) of amorphous dutybacafter. For example, in some embodiments, in a solid dispersion containing tejacarfter, the polymer is present in an amount of about 20 wt% and the amorphous tejacarfter is present in an amount of about 80 wt%. In other embodiments, a solid dispersion of amorphous dutybacarfter comprises about 19.5 wt% of polymer, about 80 wt% of amorphous dutybacarfter, and about 0.5 wt% of SLS.
[0144] In one embodiment, the solid dispersion of amorphous tezakarfter comprises about 80 percent amorphous tezakarfter based on the weight of the solid dispersion and about 20 percent HPMC based on the weight of the solid dispersion.
[0145] In one embodiment, the solid dispersion of the amorphous duty barcarfter comprises about 80 percent amorphous duty barcarfter based on the weight of the solid dispersion, about 19.5 percent HPMCAS based on the weight of the solid dispersion, and about 0.5 percent SLS based on the weight of the dispersion.
[0146] Any suitable spray-dry dispersion(s) of amorphous tezakafter and amorphous dutybafter may be used in the pharmaceutical compositions disclosed herein. Some examples of spray-dry dispersions of amorphous tezakafter and pharmaceutically acceptable salts thereof may be found in WO 2015 / 160787 and WO 2011 / 119984, the contents of which are incorporated herein by reference. Solid dispersions of non-deuterated analogs of dutybafter and methods for preparing such dispersions are disclosed in PCT Publication No. WO 2007 / 079139, which is incorporated herein by reference.
[0147] Pharmaceutical composition
[0148] In one embodiment, the present invention provides a pharmaceutical granule composition comprising a mixture of two CF corrector APIs (e.g., crystalline banjacafter calcium salt hydrate form D and amorphous tejacafter) and a CF strengthener API (e.g., amorphous dutybacafter). As exemplified herein, the pharmaceutical granule composition of the present invention may be a mixture of one or more excipients described herein and banjacafter, tejacafter, and dutybacafter. The pharmaceutical composition may be packaged in unit dosage forms containing the granules of the present invention in a specific dosage amount, e.g., tablets, capsules, sachets, troches, blister packs, etc.
[0149] In some embodiments, the present invention provides a pharmaceutical granule composition in which each granule comprises about 0.05 to about 0.2 mg of crystalline banzakafter calcium salt hydrate form D. For example, each granule may comprise about 0.05 mg, about 0.075 mg, about 0.1 mg, about 0.15 mg, or about 0.2 mg of crystalline banzakafter calcium salt hydrate form D. Each unit dosage form (e.g., a package of granules) provides about 1 mg to about 12.7 mg of crystalline banzakafter calcium salt hydrate form D. In some embodiments, the unit dosage form comprises about 4.2 mg of crystalline banzakafter calcium salt hydrate form D. In some embodiments, the unit dosage form comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D. In some embodiments, the unit dose form comprises about 8.5 mg of crystalline banzakarftor calcium salt hydrate form D. In some embodiments, the unit dose form comprises about 12.7 mg of crystalline banzakarftor calcium salt hydrate form D.
[0150] In some embodiments, the present invention provides a pharmaceutical granule composition comprising a solid dispersion in which each granule comprises about 0.25 to about 0.75 mg of amorphous tezacafter, or about 0.25 to about 0.75 mg of amorphous tezacafter. For example, each granule may comprise a solid dispersion comprising about 0.25 mg, about 0.5 mg, or about 0.75 mg of amorphous tezacafter, or about 0.3 mg, about 0.5 mg, or about 0.7 mg of amorphous tezacafter. In some embodiments, a unit dose form comprises about 16 mg of amorphous tezacafter. In some embodiments, a unit dose form comprises about 24 mg of amorphous tezacafter. In some embodiments, a unit dose form comprises about 32 mg of amorphous tezacafter. In some embodiments, a unit dose form comprises about 48 mg of amorphous tezacafter. In some embodiments, the unit dose form comprises a solid dispersion containing about 20 mg of amorphous tezakarfter. In some embodiments, the unit dose form comprises a solid dispersion containing about 30 mg of amorphous tezakarfter. In some embodiments, the unit dose form comprises a solid dispersion containing about 40 mg of amorphous tezakarfter. In some embodiments, the unit dose form comprises a solid dispersion containing about 60 mg of amorphous tezakarfter.
[0151] In some embodiments, the present invention provides a pharmaceutical granule composition comprising a solid dispersion in which each granule comprises about 1.0 to about 3.0 mg of amorphous dutybacarfter and / or about 1.0 to about 3.0 mg of amorphous dutybacarfter. For example, each granule may comprise a solid dispersion comprising about 1.0 mg, about 1.5 mg, or about 2.0 mg of dutybacarfter, or about 1.0 mg, about 2.0 mg, or about 3.0 mg of amorphous dutybacarfter. In some embodiments, a unit dose form comprises about 50 mg of amorphous dutybacarfter. In some embodiments, a unit dose form comprises about 75 mg of amorphous dutybacarfter. In some embodiments, a unit dose form comprises about 100 mg of amorphous dutybacarfter. In some embodiments, the unit dose form comprises about 150 mg of amorphous dutybacarfter. In some embodiments, the unit dose form comprises a solid dispersion comprising about 62.5 mg of amorphous dutybacarfter. In some embodiments, the unit dose form comprises a solid dispersion comprising about 94 mg of amorphous dutybacarfter. In some embodiments, the unit dose form comprises a solid dispersion comprising about 125 mg of amorphous dutybacarfter. In some embodiments, the unit dose form comprises a solid dispersion comprising about 188 mg of amorphous dutybacarfter.
[0152] In some embodiments, the present invention provides a pharmaceutical granule composition in which each granule comprises about 0.05 to about 0.5 mg of crystalline banzakafter calcium salt hydrate form D, about 0.25 to about 0.75 mg of amorphous tezakafter, and about 0.5 to about 1.0 mg of amorphous dutybakafter. In some embodiments, each granule comprises about 0.14 mg of crystalline banzakafter calcium salt hydrate form D, about 0.5 mg of amorphous tezakafter, and about 1.7 mg of amorphous dutybakafter. In some embodiments, a unit dose form comprises about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of amorphous tezakafter, and about 50 mg of amorphous dutybakafter. In some embodiments, the unit dose form comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutybakafter. In some embodiments, the unit dose form comprises about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 36 mg of amorphous tezakafter, and about 100 mg of amorphous dutybakafter. In some embodiments, the unit dose form comprises about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of amorphous tezakafter, and about 150 mg of amorphous dutybakafter.
[0153] In some embodiments, the present invention provides a pharmaceutical granule composition comprising, in each granule, a solid dispersion comprising about 0.05 to about 0.2 mg of crystalline banjacafter calcium salt hydrate form D, about 0.25 to about 0.75 mg of amorphous tejacafter, and a solid dispersion comprising about 0.5 to about 1.0 mg of amorphous dutybacafter. In some embodiments, each granule comprises about 0.1 mg of crystalline banjacafter calcium salt hydrate form D, a solid dispersion comprising about 0.7 mg of amorphous tejacafter, and a solid dispersion comprising about 2.0 mg of dutybacafter. In some embodiments, a unit dose form comprises about 4.2 mg of crystalline banjacafter calcium salt hydrate form D, a solid dispersion comprising about 20 mg of amorphous tejacafter, and a solid dispersion comprising about 60 mg of amorphous dutybacafter. In some embodiments, the unit dose form comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising about 30 mg of amorphous tezakafter, and a solid dispersion comprising about 94 mg of amorphous dutybakafter. In some embodiments, the unit dose form comprises about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising about 40 mg of amorphous tezakafter, and a solid dispersion comprising about 125 mg of amorphous dutybakafter. In some embodiments, the unit dose form comprises about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, a solid dispersion comprising about 60 mg of amorphous tezakafter, and a solid dispersion comprising about 188 mg of amorphous dutybakafter.
[0154] In addition to the solid dispersions of Tejakafter and Dutivakafter, the pharmaceutical granule composition of the present invention also comprises one or more excipients such as fillers, sweeteners, disintegrants, wetting agents, lubricants, lubricants, coloring agents, flavoring agents, or combinations thereof. It should be noted that some excipients may perform more than one function; for example, some fillers may also be sweeteners, and some disintegrants may also be wetting agents (for example, mannitol may be both a filler and a sweetener).
[0155] The fillers suitable for the present invention are compatible with the components of the pharmaceutical granule composition, that is, they do not substantially reduce the solubility, chemical stability, physical stability, or biological activity of the pharmaceutical composition. Examples of filler(s) may include, but are not limited to, mannitol, lactose, sucrose, dextrose, maltodextrin, sorbitol, xylitol, powdered cellulose, polyhydric alcohol, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose acetate, methylcellulose, ethylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose, talc, starch (i.e., potato starch), pregelatinized starch, dibasic calcium phosphate, calcium sulfate, and calcium carbonate, or combinations thereof.
[0156] In one embodiment, the filler comprises microcrystalline cellulose.
[0157] In a further embodiment, one or more fillers in the pharmaceutical granule composition of the present invention are binary fillers comprising a mixture of two fillers. In another further embodiment, the binary filler is a mixture of mannitol and another filler. In another embodiment, the binary filler is a mixture of lactose, e.g., lactose monohydrate, and another filler. In a specific embodiment, the binary filler is a mixture of mannitol and lactose, e.g., lactose monohydrate.
[0158] In some embodiments, the pharmaceutical granule composition comprises a binary filler, wherein the binary filler comprises mannitol and lactose in a ratio of about 3:1 to mannitol. In certain embodiments of the present disclosure, a binary filler with a ratio of 1 to about 3 to mannitol results in improved properties of the pharmaceutical granule composition, such as improved palatability and improved processability, without adversely affecting, for example, dispersibility, and / or bioavailability. For example, in certain embodiments, a pharmaceutical granule composition comprising a binary filler with a ratio of 1 to about 3 to mannitol has been observed to require a lower ejection force during manufacturing, even at high compression pressures, compared to a pharmaceutical composition comprising mannitol as a single filler. The ability to use a lower ejection force allows the composition to be manufactured more stably, as there is less likelihood of the composition being damaged while being ejected from the die after compression.
[0159] The pharmaceutical granule composition also includes a sweetener to mask and enhance the flavor of the composition. In some embodiments, one or more sweeteners include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. Examples of suitable sweeteners include both natural sweeteners and artificial sweeteners. Examples may include, but are not limited to, glucose, sucrose, maltose, mannose, dextrose, fructose, lactose, trehalose, maltitol, lactitol, xylitol, sorbitol, mannitol, tagatose, glycerin, erythritol, isomalt, maltose, sucralose, aspartame, neotame, alitame, neohesperidin dihydrochalcone, cyclamate (i.e., sodium cyclamate), thaumatin, acesulfame potassium, saccharin, and sodium saccharin. In certain embodiments, the sweetener contains sucralose at a concentration of about 1 wt% to about 2 wt%.
[0160] Disintegrants suitable for the present invention improve the dispersion of the pharmaceutical granule composition and are compatible with the components of the pharmaceutical composition, that is, they do not substantially reduce the chemical stability, physical stability, or biological activity of the pharmaceutical composition. Exemplary disintegrants include sodium croscarmellose (e.g., AcDiSol), sodium alginate, calcium alginate, alginic acid, starch, pregelatinized starch, sodium starch glycolate, polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone, crospovidone, calcium carboxymethylcellulose, cellulose and derivatives thereof, sodium carboxymethylcellulose, soybean polysaccharides, clay, gum (i.e., guar gum), ion exchange resins, foaming systems based on food acids and alkaline carbonate components, and sodium bicarbonate. In some embodiments, the pharmaceutical composition comprises about 4 wt% to about 8% of sodium croscarmellose based on the weight of the composition. In another example, a pharmaceutical composition contains about 6 wt% of croscarmellose sodium based on the weight of the composition.
[0161] Wetting agents and / or surfactants suitable for the present invention can improve the solubility or wettability of a pharmaceutical granule composition and are compatible with the components of the pharmaceutical composition, that is, they do not substantially reduce the chemical stability, physical stability, or biological activity of the pharmaceutical composition. In some embodiments, one or more wetting agents comprise one or more surfactants. Examples of wetting agents / surfactants may include, but are not limited to: sodium lauryl sulfate (also known as sodium dodecyl sulfate (SDS)), cetostearyl alcohol, cetomacrogol emulsifying wax, gelatin, casein, sodium docusate, benzalkonium chloride, calcium stearate, polyethylene glycol, phosphate, polyoxyethylene sorbitan fatty acid esters (e.g., polysorbate 80, polysorbate 20), acacia gum, cholesterol, tragacanth, polyoxyethylene 20 stearyl ether, polyoxyethylene alkyl ether, polyoxyethylene castor oil derivatives, pegylated hydrogenated castor oil, sorbitan esters of fatty acids, vitamin E or tocopherol derivatives, vitamin E TPGS, tocopheryl esters, lecithin, phospholipids and their derivatives, poloxamer, stearic acid, oleic acid, oleic acid alcohol, Cetyl alcohol, mono and diglycerides, propylene glycol esters of fatty acids, glycerol esters of fatty acids (i.e., glycerol monostearate), ethylene glycol palmitostearate, polyoxyglycerides, propylene glycol monocaprylate, propylene glycol monolaurate, alkyl aryl polyether alcohols (Triton®), and polyglyceryl oleates. The use of humectants in the pharmaceutical compositions of the present invention is optional.
[0162] A lubricant suitable for the present invention improves the flow characteristics of a pharmaceutical composition and is compatible with the components of the pharmaceutical composition, that is, it does not substantially reduce the solubility, chemical stability, physical stability, or biological activity of the pharmaceutical composition. A “lubricant” is a substance that promotes powder fluidity by reducing inter-particle friction and cohesive forces. In certain embodiments, one or more excipients may include one or more lubricants. Examples of lubricants may include, but are not limited to, talc, colloidal silica (e.g., Cabosil M-5P), precipitated silica, magnesium oxide, magnesium silicate, leucine, and starch. In some embodiments, the composition of the present invention contains colloidal silicon dioxide as a lubricant. In some embodiments, the pharmaceutical granule composition contains about 0.5 to about 1.5 wt% of colloidal silicon dioxide based on the weight of the composition. In certain embodiments, the pharmaceutical granule composition contains about 1.0 wt% of colloidal silicon dioxide based on the weight of the composition.
[0163] A lubricant suitable for the present invention improves the compression and ejection of a pharmaceutical composition compressed from a die. The lubricant may additionally possess anti-stick or anti-adhesion properties, minimize adhesion in various operations of the present invention including operations such as encapsulation, and be compatible with the components of the pharmaceutical composition, that is, not substantially reduce the solubility or biological activity of the pharmaceutical composition. Examples of lubricants may include, but are not limited to, talc, fatty acids, stearic acid, magnesium stearate, calcium stearate, sodium stearate, stearic acid, glyceryl monostearate, sodium lauryl sulfate, sodium stearyl fumarate, hydrogenated oil (i.e., hydrogenated vegetable oil), polyethylene glycol, fatty alcohols, fatty acid esters, glyceryl behenate, mineral oil, vegetable oil, leucine, sodium benzoate, or combinations thereof. In some embodiments, the pharmaceutical granule composition of the present invention comprises magnesium stearate as a lubricant. In some embodiments, the pharmaceutical granule composition comprises about 0.5 to about 2.0 wt% of magnesium stearate based on the weight of the composition. In certain embodiments, the pharmaceutical granule composition of the present invention comprises about 1.0 wt% of magnesium stearate based on the weight of the composition.
[0164] The pharmaceutical granule composition of the present invention may optionally include one or more coloring agents, flavoring agents, and / or flavorings to enhance the visual appeal, taste, and / or aroma of the composition. Suitable coloring agents, flavoring agents, or flavorings are compatible with the components of the pharmaceutical composition, that is, they do not substantially reduce the solubility, chemical stability, physical stability, or biological activity of the pharmaceutical composition. In one embodiment, the pharmaceutical granule composition comprises coloring agents, flavoring agents, and / or flavorings.
[0165] Suitable flavoring agents may include, for example, natural flavoring agents, artificial flavoring agents, and combinations thereof, flavoring agents known to those skilled in the art. The flavoring agents are compatible with the components of the pharmaceutical composition, that is, they do not substantially reduce the chemical stability, physical stability, or biological activity of the pharmaceutical composition. The flavoring agents may be selected from, for example, synthetic flavoring oils and flavoring aromatics and / or oils, oleoresins, extracts derived from plants, leaves, flowers, fruits, etc., and combinations thereof. Non-limiting examples of flavoring oils include spearmint oil, cinnamon oil, wintergreen oil (methyl salicylate), peppermint oil, clove oil, bay oil, anise oil, eucalyptus oil, thyme oil, cedar leaf oil, nutmeg oil, allspice, sage oil, mace, bitter almond oil, and cassia oil. Suitable flavoring agents also include artificial, natural, and synthetic floral-derived or fruit flavors, such as, for example, vanilla, ethyl vanillin, citrus oils (e.g., lemon, orange, tangerine, lime, and grapefruit), and fruit essences (e.g., natural and / or artificial flavors of apple, pear, peach, orange, grape, strawberry, raspberry, cherry, plum, pineapple, and apricot), and combinations thereof. Flavoring agents may be used in liquid or solid form and may be used individually or mixed as indicated above. Other flavoring agents may include, for example, certain aldehydes and esters, for example, cinnamyl acetate, cinnamaldehyde, citral diethylacetal, dihydrocarbyl acetate, eugenyl formate, 4-methylanisole, etc., and combinations thereof.
[0166] In some embodiments, the present invention provides a pharmaceutical granule composition that can be used to treat patients having a mutant form of human CFTR.
[0167] In another embodiment, the present invention provides a unit dosage form comprising a plurality of granules. The unit dosage form comprises a compressed powder pharmaceutical granule composition as described above, to which one or more functional excipients, e.g., disintegrants, lubricants, lubricants, fillers, and / or wetting agents are added to facilitate the compression of the powder pharmaceutical composition into a compressed pharmaceutical composition and to promote the disintegration and dissolution of the compressed powder. The compressed pharmaceutical granule composition may be formulated into unit dosage forms such as tablets, capsules, pouches, packets, sachets, bottles, and blister packs containing a plurality of such granules. The number of granules required for each unit dosage form depends on the concentrations of banja-kafter, teja-kafter, and dutiva-kafter of each granule and the required final amount of banja-kafter required for the unit dosage form. For the purpose of illustration only, a unit dose form comprising 30 granules, wherein each granule contains 0.14 mg of crystalline banzakafter calcium salt hydrate form D, 0.54 mg of amorphous tezakafter, and 1.66 mg of amorphous dutybakafter, can deliver a unit dose of 4.2 mg of crystalline banzakafter calcium salt hydrate form D, 16.1 mg of amorphous tezakafter, and 49.9 mg of amorphous dutybakafter.
[0168] In some embodiments, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0169] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0170] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0171] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0172] d. One or more fillers;
[0173] e. Disintegrant;
[0174] f. sweetener;
[0175] g. lubricant; and
[0176] h. Includes lubricant;
[0177] Here, the unit dosage forms include crystalline banzakafter calcium salt hydrate form D in amounts ranging from about 1 mg to about 12.7 mg, amorphous tezakafter in amounts ranging from about 10 mg to about 50 mg, and amorphous dutybakafter in amounts ranging from about 15 mg to about 150 mg.
[0178] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0179] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0180] b. A solid dispersion comprising Tejakarfter and a first polymer;
[0181] c. A solid dispersion comprising a duty barcarfter and a second polymer;
[0182] d. One or more fillers;
[0183] e. Disintegrant;
[0184] f. sweetener;
[0185] g. lubricant; and
[0186] h. Includes lubricant;
[0187] Herein, the unit dosage form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0188] Here, Tejakafter and / or Dutivakafter are substantially in an amorphous form;
[0189] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0190] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0191] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0192] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0193] d. One or more fillers;
[0194] e. Disintegrant;
[0195] f. sweetener;
[0196] g. lubricant; and
[0197] h. Includes lubricant;
[0198] Herein, the unit dose form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0199] Here, the banjakaftor calcium salt hydrate form D is characterized by an X-ray powder diffraction pattern having signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees.
[0200] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0201] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0202] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0203] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0204] d. One or more fillers;
[0205] e. Disintegrant;
[0206] f. sweetener;
[0207] g. lubricant; and
[0208] h. Includes lubricant;
[0209] Herein, the unit dose form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0210] Here, the banjakaftor calcium salt hydrate form D is characterized by an X-ray powder diffraction pattern having (a) signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees; and (b) one or more signals selected from 5.5 ± 0.2 2-theta degrees, 15.5 ± 0.2 2-theta degrees, 19.7 ± 0.2 2-theta degrees, 21.5 ± 0.2 2-theta degrees, 22.1 ± 0.2 2-theta degrees, 23.0 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees.
[0211] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0212] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0213] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0214] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0215] d. One or more fillers;
[0216] e. Disintegrant;
[0217] f. sweetener;
[0218] g. lubricant; and
[0219] h. Includes lubricant;
[0220] Herein, the unit dose form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0221] Here, the banjakaftor calcium salt hydrate form D is characterized by (a) signals at 6.1 ± 0.2 2-theta degrees, 16.2 ± 0.2 2-theta degrees, and 22.8 ± 0.2 2-theta degrees; and (b) X-ray powder diffraction having two or more signals selected from 5.5 ± 0.2 2-theta degrees, 15.5 ± 0.2 2-theta degrees, 19.7 ± 0.2 2-theta degrees, 21.5 ± 0.2 2-theta degrees, 22.1 ± 0.2 2-theta degrees, 23.0 ± 0.2 2-theta degrees, and 27.6 ± 0.2 2-theta degrees.
[0222] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0223] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0224] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0225] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0226] d. One or more fillers;
[0227] e. Disintegrant;
[0228] f. sweetener;
[0229] g. lubricant; and
[0230] h. Includes lubricant;
[0231] Herein, the unit dose form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0232] Here, the form D of the banzakafter calcium salt hydrate features an X-ray powder diffraction pattern substantially similar to that of Fig. 1.
[0233] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0234] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0235] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0236] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0237] d. One or more fillers;
[0238] e. Disintegrant;
[0239] f. sweetener;
[0240] g. lubricant; and
[0241] h. Includes lubricant;
[0242] Here, the unit dose forms include about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of amorphous tezakafter, and about 50 mg of amorphous dutybakafter.
[0243] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0244] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0245] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0246] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0247] d. One or more fillers;
[0248] e. Disintegrant;
[0249] f. sweetener;
[0250] g. lubricant; and
[0251] h. Includes lubricant;
[0252] Here, the unit dose forms include about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutybakafter.
[0253] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0254] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0255] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0256] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0257] d. One or more fillers;
[0258] e. Disintegrant;
[0259] f. sweetener;
[0260] g. lubricant; and
[0261] h. Includes lubricant;
[0262] Here, the unit dose forms include about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of amorphous tezakafter, and about 100 mg of amorphous dutybakafter.
[0263] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0264] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0265] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0266] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0267] d. One or more fillers;
[0268] e. Disintegrant;
[0269] f. sweetener;
[0270] g. lubricant; and
[0271] h. Includes lubricant;
[0272] Here, the unit dose forms include about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of amorphous tezakafter, and about 150 mg of amorphous dutybakafter.
[0273] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0274] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0275] b. A solid dispersion comprising approximately 80 wt% of amorphous Tejacarfter and approximately 20 wt% of HPMC based on the weight of the dispersion;
[0276] c. A solid dispersion comprising, based on the weight of the dispersion, approximately 80 wt% of amorphous duty barcarfter, approximately 19.5 wt% of HPMCAS, and approximately 0.5 wt% of SLS;
[0277] d. A binary filler composed of mannitol and lactose;
[0278] e. Croscarmellose sodium;
[0279] f. Sucralose;
[0280] g. Colloidal silicon dioxide; and
[0281] h. Contains magnesium stearate;
[0282] Here, the unit dose forms include crystalline banzakafter calcium salt hydrate form D in amounts ranging from about 1 mg to about 12.7 mg, amorphous tezakafter in amounts ranging from about 10 mg to about 50 mg, and amorphous dutybakafter in amounts ranging from about 15 mg to about 150 mg.
[0283] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0284] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0285] b. A solid dispersion containing approximately 80 wt% amorphous Tejacarfter and approximately 20 wt% HPMC;
[0286] c. A solid dispersion containing approximately 80 wt% amorphous duty barcarfter, approximately 19.5 wt% HPMCAS, and approximately 0.5 wt% SLS;
[0287] d. A binary filler composed of mannitol and lactose;
[0288] e. Croscarmellose sodium;
[0289] f. Sucralose;
[0290] g. Colloidal silicon dioxide; and
[0291] h. Contains magnesium stearate;
[0292] Here, the unit dose forms include about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of amorphous tezakafter, and about 50 mg of amorphous dutybakafter.
[0293] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0294] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0295] b. A solid dispersion containing approximately 80 wt% amorphous Tejacarfter and approximately 20 wt% HPMC;
[0296] c. A solid dispersion containing approximately 80 wt% amorphous duty barcarfter, approximately 19.5 wt% HPMCAS, and approximately 0.5 wt% SLS;
[0297] d. A binary filler composed of mannitol and lactose;
[0298] e. Croscarmellose sodium;
[0299] f. Sucralose;
[0300] g. Colloidal silicon dioxide; and
[0301] h. Contains magnesium stearate;
[0302] Here, the unit dose forms include about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutybakafter.
[0303] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0304] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0305] b. A solid dispersion containing approximately 80 wt% amorphous Tejacarfter and approximately 20 wt% HPMC;
[0306] c. A solid dispersion containing approximately 80 wt% amorphous duty barcarfter, approximately 19.5 wt% HPMCAS, and approximately 0.5 wt% SLS;
[0307] d. A binary filler composed of mannitol and lactose;
[0308] e. Croscarmellose sodium;
[0309] f. Sucralose;
[0310] g. Colloidal silicon dioxide; and
[0311] h. Contains magnesium stearate;
[0312] Here, the unit dose forms include about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of amorphous tezakafter, and about 100 mg of amorphous dutybakafter.
[0313] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0314] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0315] b. A solid dispersion containing approximately 80 wt% amorphous Tejacarfter and approximately 20 wt% HPMC;
[0316] c. A solid dispersion containing approximately 80 wt% amorphous duty barcarfter, approximately 19.5 wt% HPMCAS, and approximately 0.5 wt% SLS;
[0317] d. A binary filler composed of mannitol and lactose;
[0318] e. Croscarmellose sodium;
[0319] f. Sucralose;
[0320] g. Colloidal silicon dioxide; and
[0321] h. Contains magnesium stearate;
[0322] Here, the unit dose forms include about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of amorphous tezakafter, and about 150 mg of amorphous dutybakafter.
[0323] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0324] a. Approximately 2 wt% of crystalline banjacafter calcium salt hydrate form D based on the weight of the composition;
[0325] b. Approximately 10 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous tejacarfter and approximately 20 wt% of HPMC based on the weight of the dispersion -;
[0326] c. Approximately 30 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous duty barcarfter, approximately 19.5 wt% of HPMCAS, and approximately 0.5 wt% of SLS based on the weight of the dispersion -;
[0327] d. One or more fillers of about 48 wt% based on the weight of the composition;
[0328] e. Approximately 6 wt% of a disintegrant based on the weight of the composition;
[0329] f. About 2 wt% of sweetener based on the weight of the composition;
[0330] g. About 1 wt% of a lubricant based on the weight of the composition; and
[0331] h. It comprises about 1 wt% of a lubricant based on the weight of the composition;
[0332] Here, the unit dose forms include about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of amorphous tezakafter, and about 50 mg of amorphous dutybakafter.
[0333] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0334] a. Approximately 2 wt% of crystalline banjacafter calcium salt hydrate form D based on the weight of the composition;
[0335] b. Approximately 10 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous tejacarfter and approximately 20 wt% of HPMC based on the weight of the dispersion -;
[0336] c. Approximately 30 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous duty barcarfter, approximately 19.5 wt% of HPMCAS, and approximately 0.5 wt% of SLS based on the weight of the dispersion -;
[0337] d. One or more fillers of about 48 wt% based on the weight of the composition;
[0338] e. Approximately 6 wt% of a disintegrant based on the weight of the composition;
[0339] f. About 2 wt% of sweetener based on the weight of the composition;
[0340] g. About 1 wt% of a lubricant based on the weight of the composition; and
[0341] h. It comprises about 1 wt% of a lubricant based on the weight of the composition;
[0342] Here, the unit dose forms include about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutybakafter.
[0343] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0344] a. Approximately 2 wt% of crystalline banjacafter calcium salt hydrate form D based on the weight of the composition;
[0345] b. Approximately 10 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous tejacarfter and approximately 20 wt% of HPMC based on the weight of the dispersion -;
[0346] c. Approximately 30 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous duty barcarfter, approximately 19.5 wt% of HPMCAS, and approximately 0.5 wt% of SLS based on the weight of the dispersion -;
[0347] d. One or more fillers of about 48 wt% based on the weight of the composition;
[0348] e. Approximately 6 wt% of a disintegrant based on the weight of the composition;
[0349] f. About 2 wt% of sweetener based on the weight of the composition;
[0350] g. About 1 wt% of a lubricant based on the weight of the composition; and
[0351] h. It comprises about 1 wt% of a lubricant based on the weight of the composition;
[0352] Here, the unit dose forms include about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of amorphous tezakafter, and about 100 mg of amorphous dutybakafter.
[0353] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0354] a. Approximately 2 wt% of crystalline banjacafter calcium salt hydrate form D based on the weight of the composition;
[0355] b. Approximately 10 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous tejacarfter and approximately 20 wt% of HPMC based on the weight of the dispersion -;
[0356] c. Approximately 30 wt% of a solid dispersion based on the weight of the composition - wherein the solid dispersion comprises approximately 80 wt% of amorphous duty barcarfter, approximately 19.5 wt% of HPMCAS, and approximately 0.5 wt% of SLS based on the weight of the dispersion -;
[0357] d. One or more fillers of about 48 wt% based on the weight of the composition;
[0358] e. Approximately 6 wt% of a disintegrant based on the weight of the composition;
[0359] f. About 2 wt% of sweetener based on the weight of the composition;
[0360] g. About 1 wt% of a lubricant based on the weight of the composition; and
[0361] h. It comprises about 1 wt% of a lubricant based on the weight of the composition;
[0362] Here, the unit dose forms include about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of amorphous tezakafter, and about 150 mg of amorphous dutybakafter.
[0363] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0364] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0365] b. A solid dispersion containing approximately 80 wt% amorphous Tejacarfter and approximately 20 wt% HPMC;
[0366] c. A solid dispersion containing approximately 80 wt% amorphous duty barcarfter, approximately 19.5 wt% HPMCAS, and approximately 0.5 wt% SLS;
[0367] d. A binary filler composed of mannitol and lactose;
[0368] e. Croscarmellose sodium;
[0369] f. Sucralose;
[0370] g. Colloidal silicon dioxide; and
[0371] h. Contains magnesium stearate;
[0372] Herein, the unit dose form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0373] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0374] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0375] b. A solid dispersion containing approximately 80 wt% amorphous Tejacarfter and approximately 20 wt% HPMC;
[0376] c. A solid dispersion containing approximately 80 wt% amorphous duty barcarfter, approximately 19.5 wt% HPMCAS, and approximately 0.5 wt% SLS;
[0377] d. A binary filler composed of mannitol and lactose;
[0378] e. Croscarmellose sodium;
[0379] f. Sucralose;
[0380] g. Colloidal silicon dioxide; and
[0381] h. Contains magnesium stearate;
[0382] Herein, the unit dose form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0383] Here, mannitol is present at approximately 12.1 wt%.
[0384] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0385] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0386] b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer;
[0387] c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer;
[0388] d. One or more fillers;
[0389] e. Disintegrant;
[0390] f. sweetener;
[0391] g. lubricant; and
[0392] h. Includes lubricant;
[0393] Here, each granule contains about 0.14 mg of crystalline banzakafter calcium salt hydrate form D, about 0.54 mg of amorphous tezakafter, and about 1.66 mg of amorphous dutybakafter.
[0394] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0395] a. Crystalline Banjacarpter calcium salt hydrate form D;
[0396] b. A solid dispersion containing approximately 80 wt% amorphous Tejacarfter and approximately 20 wt% HPMC;
[0397] c. A solid dispersion containing approximately 80 wt% amorphous duty barcarfter, approximately 19.5 wt% HPMCAS, and approximately 0.5 wt% SLS;
[0398] d. A binary filler composed of mannitol and lactose;
[0399] e. Croscarmellose sodium;
[0400] f. Sucralose;
[0401] g. Colloidal silicon dioxide; and
[0402] h. Contains magnesium stearate;
[0403] Herein, the unit dose form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg;
[0404] Here, the unit dosage form contains about 30 granules.
[0405] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0406] a. About 1 to about 5 percent of the weight of the pharmaceutical composition, crystalline banjacafter calcium salt hydrate form D,
[0407] b. A solid dispersion of amorphous tejacarfter in an amount of about 8 to about 12 percent by weight of the pharmaceutical composition;
[0408] c. A solid dispersion of amorphous duty carber in an amount of about 25 to about 35 percent by weight of the pharmaceutical composition;
[0409] d. Sucralose in an amount of about 1 to about 3 percent based on the weight of the pharmaceutical composition;
[0410] e. About 1 to about 10 percent of croscarmellose sodium by weight of the pharmaceutical composition;
[0411] f. Colloidal silicon dioxide in an amount of about 0.1 to about 5 percent based on the weight of the pharmaceutical composition;
[0412] g. Magnesium stearate in an amount of about 0.5 to about 2.0 percent based on the weight of the pharmaceutical composition;
[0413] h. About 10 to about 15 percent of mannitol based on the weight of the pharmaceutical composition; and
[0414] i. It comprises an amount of lactose monohydrate of about 30 to about 40 percent based on the weight of the pharmaceutical composition;
[0415] Here, the unit dosage forms include about 0.1 to about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 10 to about 50 mg of amorphous tezakafter, and about 15 to about 150 mg of amorphous dutivakafter.
[0416] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0417] a. About 2 percent of the weight of the pharmaceutical composition, crystalline banjacafter calcium salt hydrate form D,
[0418] b. A solid dispersion of amorphous tejacarfter in an amount of about 10 percent by weight of the pharmaceutical composition;
[0419] c. A solid dispersion of amorphous duty carber in an amount of about 30 percent by weight of the pharmaceutical composition;
[0420] d. Sucralose in an amount of about 2.3 percent based on the weight of the pharmaceutical composition;
[0421] e. About 6 percent of the weight of the pharmaceutical composition is sodium croscarmellose;
[0422] f. About 1 percent of colloidal silicon dioxide by weight of the pharmaceutical composition;
[0423] g. Magnesium stearate in an amount of about 1 percent based on the weight of the pharmaceutical composition;
[0424] h. About 12 percent of the weight of the pharmaceutical composition in an amount of mannitol; and
[0425] i. It comprises an amount of lactose monohydrate of about 36 percent by weight of the pharmaceutical composition;
[0426] Here, the unit dosage forms include about 4.2 mg of crystalline banzacarfter calcium salt hydrate form D, about 16 mg of amorphous tezacarfter, and about 50 mg of amorphous dutivacarfter.
[0427] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0428] a. About 2 percent of the weight of the pharmaceutical composition, crystalline banjacafter calcium salt hydrate form D,
[0429] b. A solid dispersion of amorphous tejacarfter in an amount of about 10 percent by weight of the pharmaceutical composition;
[0430] c. A solid dispersion of amorphous duty carber in an amount of about 30 percent by weight of the pharmaceutical composition;
[0431] d. Sucralose in an amount of about 2.3 percent based on the weight of the pharmaceutical composition;
[0432] e. About 6 percent of the weight of the pharmaceutical composition is sodium croscarmellose;
[0433] f. About 1 percent of colloidal silicon dioxide by weight of the pharmaceutical composition;
[0434] g. Magnesium stearate in an amount of about 1 percent based on the weight of the pharmaceutical composition;
[0435] h. About 12 percent of the weight of the pharmaceutical composition in an amount of mannitol; and
[0436] i. It comprises an amount of lactose monohydrate of about 36 percent by weight of the pharmaceutical composition;
[0437] Here, the unit dosage forms include about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutivakafter.
[0438] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0439] a. About 2 percent of the weight of the pharmaceutical composition, crystalline banjacafter calcium salt hydrate form D,
[0440] b. A solid dispersion of amorphous tejacarfter in an amount of about 10 percent by weight of the pharmaceutical composition;
[0441] c. A solid dispersion of amorphous duty carber in an amount of about 30 percent by weight of the pharmaceutical composition;
[0442] d. Sucralose in an amount of about 2.3 percent based on the weight of the pharmaceutical composition;
[0443] e. About 6 percent of the weight of the pharmaceutical composition is sodium croscarmellose;
[0444] f. About 1 percent of colloidal silicon dioxide by weight of the pharmaceutical composition;
[0445] g. Magnesium stearate in an amount of about 1 percent based on the weight of the pharmaceutical composition;
[0446] h. About 12 percent of the weight of the pharmaceutical composition in an amount of mannitol; and
[0447] i. It comprises an amount of lactose monohydrate of about 36 percent by weight of the pharmaceutical composition;
[0448] Here, the unit dosage forms include about 8.5 mg of crystalline banzacarfter calcium salt hydrate form D, about 32 mg of amorphous tezacarfter, and about 100 mg of amorphous dutivacarfter.
[0449] In another aspect, the present invention comprises a pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each granule is
[0450] a. About 2 percent of the weight of the pharmaceutical composition, crystalline banjacafter calcium salt hydrate form D,
[0451] b. A solid dispersion of amorphous tejacarfter in an amount of about 10 percent by weight of the pharmaceutical composition;
[0452] c. A solid dispersion of amorphous duty carber in an amount of about 30 percent by weight of the pharmaceutical composition;
[0453] d. Sucralose in an amount of about 2.3 percent based on the weight of the pharmaceutical composition;
[0454] e. About 6 percent of the weight of the pharmaceutical composition is sodium croscarmellose;
[0455] f. About 1 percent of colloidal silicon dioxide by weight of the pharmaceutical composition;
[0456] g. Magnesium stearate in an amount of about 1 percent based on the weight of the pharmaceutical composition;
[0457] h. About 12 percent of the weight of the pharmaceutical composition in an amount of mannitol; and
[0458] i. It comprises an amount of lactose monohydrate of about 36 percent by weight of the pharmaceutical composition;
[0459] Here, the unit dosage forms include about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of amorphous tezakafter, and about 150 mg of amorphous dutivakafter.
[0460] Administration of a pharmaceutical composition
[0461] In another aspect, the present invention also provides a method for treating or reducing the severity of a disease in a patient, comprising the step of administering one of the pharmaceutical compositions defined herein to said patient. In some embodiments, the disease is cystic fibrosis.
[0462] In some embodiments, the method of administration of the present invention comprises the step of orally administering a liquid or beverage, including but not limited to milk (including breast milk), infant formula, or baby formula, or a soft food, including but not limited to apple sauce, plain yogurt, ice cream, or baby food (including carrots and carrot puree), in which a unit dose form of the pharmaceutical composition of the present invention is sprinkled. It is noted that any method of administration of the present invention may optionally comprise the step of orally administering with a fat-containing food, such as a standard CF-high-calorie, high-fat meal or snack. In some embodiments, any method of administration of the present invention may optionally comprise the step of orally administering with, before, or after a fat-containing food, such as a standard CF-high-calorie, high-fat meal or snack.
[0463] Additionally, it is noted that the method of administration of the present invention includes the step of administering the composition of the present invention to a patient according to age or weight. In some embodiments, the method of administering the pharmaceutical composition includes the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient is 12 to 24 months or 2 to 5 years of age. In another embodiment, the method of administering the pharmaceutical composition includes the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient includes, but is not limited to, a patient having a weight of about 14 kilograms or more. In another embodiment, the method of administering the pharmaceutical composition includes the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient includes, but is not limited to, a patient having a weight of less than 14 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 7.5 kilograms to less than 14 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 5 kilograms to less than 7.5 kilograms.In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 2.5 kilograms to less than 5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of less than 7.5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 5 kilograms to more than 5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of less than 5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules every 24 hours, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 2.5 kilograms to more than 2.5 kilograms.
[0464] Additionally, it is noted that the method of administration of the present invention includes the step of administering the composition of the present invention to a patient according to age or weight. In some embodiments, the method of administering the pharmaceutical composition includes the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient is 12 to 24 months or 2 to 5 years of age. In another embodiment, the method of administering the pharmaceutical composition includes the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient includes, but is not limited to, a patient having a weight of about 14 kilograms or more. In another embodiment, the method of administering the pharmaceutical composition includes the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient includes, but is not limited to, a patient having a weight of less than 14 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 7.5 kilograms to less than 14 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 5 kilograms to less than 7.5 kilograms.In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 2.5 kilograms to less than 5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of less than 7.5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains a pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 5 kilograms to more than 5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of less than 5 kilograms. In another embodiment, a method for administering a pharmaceutical composition comprises the step of orally administering to a patient at least one capsule or packet containing a plurality of granules once a day, wherein each granule contains the pharmaceutical composition as described herein, and wherein the patient includes a patient having a body weight of about 2.5 kilograms to more than 2.5 kilograms.
[0465] In some embodiments, the patient has at least one F508del mutation in the CFTR gene. In some embodiments, the patient has a CFTR gene mutation that is responsive to the compound, tautomer, deuterium derivative, or pharmaceutically acceptable salt of the present invention based on in vitro data. In some embodiments, the patient has a CFTR gene mutation that is responsive to the compound, tautomer, deuterium derivative, or pharmaceutically acceptable salt of the present invention based on clinical data. In some embodiments, the patient is heterozygous and has an F508del mutation in one allele and a mutation in another allele selected from Table 1:
[0466] Table 1: CFTR mutations
[0467]
[0468] In some embodiments, the method comprises the step of treating or reducing the severity of cystic fibrosis in a patient, which comprises the step of administering a pharmaceutical composition comprising a compressed pharmaceutical composition to the patient. In one embodiment, a capsule pharmaceutical composition comprising unit dosage forms of about 1 mg to about 12.7 mg of banzacafter calcium salt hydrate form D, about 10 mg to about 50 mg of amorphous tezacafter, and about 15 mg to about 150 mg of amorphous dutivacafter is administered to the patient.
[0469] In some embodiments, the method comprises the step of treating or reducing the severity of cystic fibrosis in a patient, which comprises the step of administering to the patient a capsule or packet containing a plurality of granules comprising a unit dosage form of the compressed pharmaceutical composition of the present invention, namely, about 4.2 mg of banzakafter calcium salt hydrate form D, about 20 mg of tezakafter, and about 60 mg of dutivakafter. In some embodiments, the method comprises the step of treating or reducing the severity of cystic fibrosis in a patient, which comprises the step of administering to the patient a capsule or packet containing a plurality of granules comprising a unit dosage form of the compressed pharmaceutical composition of the present invention, namely, about 6.4 mg of banzakafter calcium salt hydrate form D, about 24 mg of tezakafter, and about 75 mg of dutivakafter. In some embodiments, the method comprises the step of treating or reducing the severity of cystic fibrosis in a patient, which comprises administering to the patient a capsule or packet containing a plurality of granules comprising a unit dosage form of the compressed pharmaceutical composition of the present invention, namely, about 8.5 mg of banzakafter calcium salt hydrate form D, about 32 mg of tezakafter, and about 100 mg of dutivakafter. In some embodiments, the method comprises the step of treating or reducing the severity of cystic fibrosis in a patient, which comprises administering to the patient a capsule or packet containing a plurality of granules comprising a unit dosage form of the compressed pharmaceutical composition of the present invention, namely, about 12.7 mg of banzakafter calcium salt hydrate form D, about 48 mg of tezakafter, and about 150 mg of dutivakafter.
[0470] Additionally, it is noted that the method of administration of the present invention may optionally include the step of orally administering a pharmaceutical composition as described herein in the absence of food or beverage. In one embodiment of the present invention, oral administration is performed immediately after the patient consumes a meal or beverage or shortly thereafter (e.g., within about 30 minutes). In another embodiment, oral administration is performed at least 1 hour after the patient consumes a meal or beverage (e.g., at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 8 hours, at least 12 hours, or at least 24 hours). For example, in one example, the method of administering the pharmaceutical composition includes the step of orally administering to a patient the contents of at least one capsule or packet or pouch containing a plurality of granules once a day, each granule containing banjacafter, tejacafter, and dutivacafter, one or more fillers, sweeteners, disintegrants, optionally humectants, lubricants; and lubricants, and other therapeutic agents or medical procedures. The specific combination of therapies (therapeutics or procedures) to be used in a combination regimen will take into account the compatibility of the desired therapeutic agents and / or procedures and the desired therapeutic effect to be achieved. Additionally, it will be understood that the therapies used may achieve the desired effect for the same disorder (e.g., compounds of the present invention may be administered concurrently with other agents used to treat the same disorder), or achieve different effects (e.g., control of any side effects). As used herein, additional therapeutic agents typically administered to treat or prevent a specific disease or condition are known to be "appropriate for the disease or condition being treated."
[0471] In one embodiment, additional therapeutic agents are selected from mucolytics, bronchodilators, antibiotics, anti-infectives, anti-inflammatory agents, or nutritional agents.
[0472] In one embodiment, the additional agent is an antibiotic. Exemplary antibiotics useful herein include tobramycin comprising tobramycin inhalation powder (TIP), azithromycin, aztreonam comprising aztreonam in an aerosolized form, amikacin comprising a liposomal formulation thereof, ciprofloxacin comprising a formulation thereof suitable for administration by inhalation, levofloxacin comprising aerosolized formulation thereof, and combinations of two antibiotics, e.g., fosfomycin and tobramycin.
[0473] In another embodiment, the additional agent is a mucolytic. An exemplary mucolytic useful herein includes Pulmozyme®.
[0474] In another embodiment, the additional agent is a bronchodilator. Exemplary bronchodilators include albuterol, metaproterenol sulfate, pirbuterol acetate, salmeterol, or terbutalin sulfate.
[0475] In another embodiment, additional agents are effective in restoring the surface fluid of the lung airways. These agents improve the movement of salts into and out of cells, thereby allowing mucus in the lung airways to be better hydrated and consequently more easily expelled. Exemplary such agents include hypertonic saline, denufosol tetrasodium ([[(3 S ,5 R )-5-(4-amino-2-oxopyrimidine-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl][[[(2 R ,3 S ,4 R ,5 R It includes )-5-(2,4-dioxopyrimidine-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]hydrogen phosphate), or bronchitol (mannitol in an inhalation formulation).
[0476] In another embodiment, the additional agent is an anti-inflammatory agent, that is, an agent capable of reducing inflammation of the lungs. Exemplary such agents useful herein include ibuprofen, docosahexaenoic acid (DHA), sildenafil, inhaled glutathione, pioglitazone, hydroxychloroquine, or simavastatin.
[0477] In another embodiment, the additional agent is a CFTR modulator other than banzakarpter, i.e., an agent having the effect of modulating CFTR activity. Exemplary such agents are ataluren ("PTC124®"; 3-[5-(2-fluorophenyl)-1,2,4-oxadiazole-3-yl]benzoic acid), sinapultide, lancobutide, defelestat (human recombinant neutrophil elastase inhibitor), cobiprostone (7-{(2 R ,4a R ,5 R ,7a R )-2-[(3 S )-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxo-octahydrocyclopenta[ b ]pyran-5-yl}heptanoic acid), or (3-(6-(1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridine-2-yl)benzoic acid is included. In another embodiment, additional formulations include (3-(6-(1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridine-2-yl)benzoic acid.
[0478] In another embodiment, the additional formulation is a nutritional supplement. Exemplary such formulations include pancrelipase (pancreatic enzyme replacement), including Pancrease®, Pancreacarb®, Ultrase®, or Creon®, Liprotamase® (formerly Trizytek®), Aquadeks®, or glutathione inhalants. In one embodiment, the additional nutritional supplement is pancrelipase.
[0479] Examples
[0480] To enable a more complete understanding of the invention described herein, the following examples are provided. These examples are to be understood as being for illustrative purposes only and not as limiting the invention in any way.
[0481] weak
[0482] ACN = Acetonitrile
[0483] AUC = Area under the curve
[0484] Boc = Burst -Butyloxycarbonyl
[0485] DCM = Dichloromethane
[0486] DMF = Dimethylformamide
[0487] DMSO = Dimethyl sulfoxide
[0488] ESI = Electrospray ionization
[0489] FTNMR = Fourier Transform Nuclear Magnetic Resonance
[0490] HPLC = High-performance liquid chromatography
[0491] HPMC = Hydroxypropyl Methylcellulose
[0492] HPMCAS = Hydroxypropylmethylcellulose acetate succinate
[0493] IPA = Isopropyl alcohol
[0494] IPAc = Isopropyl Acetate
[0495] KF = Karl Fischer titration method
[0496] LC = Liquid Chromatography
[0497] LCMS = Liquid Chromatography-Mass Spectrometry
[0498] MeTHF = 2-methyltetrahydrofuran
[0499] MS = Mass Spectrometry
[0500] MTBE = Methyl Burst -butyl ether
[0501] NMR = Nuclear Magnetic Resonance
[0502] pn = part number
[0503] SDD = Spray-dried dispersion
[0504] SFC = Supercritical Fluid Chromatography
[0505] SLS = Sodium Lauryl Sulfate
[0506] THF = Tetrahydrofuran
[0507] TLC = Thin-layer chromatography
[0508] UPLC = Ultra-high Performance Liquid Chromatography
[0509] UV = Ultraviolet rays
[0510] wt% = weight percentage
[0511] General UPLC / HPLC analysis methods
[0512] Unless otherwise specified, the yield of enantiomers separated by chiral SFCs is provided as a percentage of the theoretical yield of a single enantiomer of a racemic mixture.
[0513] LC Method A: Acquity UPLC BEH C prepared by Waters 18 Analytical reversed-phase UPLC using column (30 × 2.1 mm, 1.7 μm particles) (pn: 186002349), and double gradient run from 1–99% mobile phase B over 1.2 min. Mobile phase A = water (0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (0.035% trifluoroacetic acid). Flow rate = 1.5 mL / min, injection volume = 1.5 μL, and column temperature = 60°C.
[0514] LC Method B: Acquity UPLC BEH C prepared by Waters 18Analytical reversed-phase UPLC using a column (50 × 2.1 mm, 1.7 μm particles) (pn: 186002350), and a double gradient run from 1–99% mobile phase B over 3.0 min. Mobile phase A = water (0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60°C.
[0515] LC Method D: Acquity UPLC BEH C prepared by Waters 18 Analytical reversed-phase UPLC using a column (50 × 2.1 mm, 1.7 μm particles) (pn: 186002350), and a double gradient run from 1–99% mobile phase B over 5.0 min. Mobile phase A = water (0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60°C.
[0516] LC Method F: Acquity UPLC BEH C prepared by Waters 18 Analytical reversed-phase UPLC using a column (50 × 2.1 mm, 1.7 μm particles) (pn: 186002350), and a double gradient run from 1–99% mobile phase B over 15.0 min. Mobile phase A = water (0.05% trifluoroacetic acid). Mobile phase B = acetonitrile (0.035% trifluoroacetic acid). Flow rate = 1.2 mL / min, injection volume = 1.5 μL, and column temperature = 60°C.
[0517] LC Method Q: Merck Millipore Chromolith SpeedROD C 18 Double gradient run from 5–100% mobile phase B over 12 minutes on a column (50 x 4.6 mm). Mobile phase A = water (0.1% trifluoroacetic acid). Mobile phase B = acetonitrile (0.1% trifluoroacetic acid).
[0518] Example 1: Synthesis of Banjakafter calcium salt hydrate form D
[0519] Part A. (14 S )-8-bromo-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 Synthesis of ]tetracosa-1(23),5,7,9,19,21-hexane-2,2,4-trione
[0520] Step 1: ( E )-(2-oxotetrahydropyran-3-ylidene)methanolate (sodium salt)
[0521]
[0522] A 5L, three-necked round-bottom flask was equipped with a mechanical stirrer, a heating mantle, an addition funnel, a J-Kem temperature probe / controller, and nitrogen inlets / outlets. Under a nitrogen atmosphere, the vessel was filled with sodium hydride (59.91 g, 60% w / w, 1.498 mol) followed by heptane (1.5 L) to obtain a gray suspension. Stirring was started, and the port temperature was recorded at 19°C. Then, the vessel [was] syringe throughThe mixture was filled with added ethyl alcohol (3.451 g, 74.91 mmol), which generated gas. The addition funnel was filled with a clear pale yellow solution of tetrahydropyran-2-one (150 g, 1.498 mol) and ethyl formate (111 g, 1.50 mol). The solution was added dropwise over 1 hour, which generated gas and gradually heated to 45°C. The resulting thick white suspension was then heated to 65°C for 2 hours and cooled to room temperature. The mixture was continuously stirred overnight (approximately 10 hours) at room temperature. The reaction mixture was vacuum filtered through a glass Fritt-Buchner funnel (moderate porosity) under a nitrogen stream. The filter cake was washed with heptane (2 x 250 mL) and aspirated for a few minutes. Transfer the cake slightly moistened with heptane to a glass tray and dry it in a vacuum oven at 45°C for 15 hours to obtain the desired product, ( E )-(2-oxotetrahydropyran-3-ylidene)methanolate (sodium salt) was obtained as a white solid (205 g, 1.36 mol, 91% yield).
[0523] Step 2: 3-methylenetetrahydropyran-2-one
[0524]
[0525] A 5L, three-necked round-bottom flask was equipped with a mechanical stirrer, a heating mantle, an addition funnel, a J-Kem temperature probe / controller, and nitrogen inlets / outlets. The vessel was placed under a nitrogen atmosphere ( EA white suspension was obtained by filling with )-(2-oxotetrahydropyran-3-ylidene)methanolate (sodium salt) (205 g, 1.366 mol) (205 g, 1.366 mol) and tetrahydrofuran (1640 mL). Stirring was started, and the pot temperature was recorded at 19°C. Then, the container was filled with paraformaldehyde (136.6 g, 4.549 mol) and added in one solid. The resulting suspension was heated to 63°C and maintained in this state for 15 hours. Upon heating, the reaction mixture became slightly gelatinized. The white gelatin mixture was concentrated under reduced pressure to remove most of the tetrahydrofuran. The remaining residue was distributed in a separatory funnel with ethyl acetate (1000 mL), saturated sodium chloride (500 mL), and saturated sodium bicarbonate (500 mL). The organic layer was removed, and the residual aqueous layer was extracted with ethyl acetate (5 x 300 mL). The combined organic layer was dried over sodium sulfate (500 g) and then vacuum filtered through a glass Fritt Buchner funnel with a 20 mm celite layer. The filter cake was washed with ethyl acetate (250 mL). The clear filtrate was concentrated under reduced pressure to obtain a clear pale yellow oil (135 g) as the desired crude product. A 450 mL fraction was collected by eluting the material over 1 hour in a gradient of 100% hexane to 60% ethyl acetate in hexane, and the product was purified by silica gel column flash chromatography (liquid loading). The product was detected by TLC analysis on a silica gel eluted with 3:1 hexane / ethyl acetate and visualized under UV. The product fractions were combined and concentrated under reduced pressure to obtain the desired product, 3-methylenetetrahydropyran-2-one, as a clear, colorless oil (132 g, 1.18 mol, 72% yield containing 16 wt% residual ethyl acetate as determined by NMR). 1H NMR (400 MHz, dimethyl sulfoxide-d6) δ 6.18 (q, J= 1.9 Hz, 1H), 5.60 (q, J = 1.9 Hz, 1H), 4.40 - 4.26 (m, 2H), 2.61 (ddt, J = 7.0, 6.3, 2.0 Hz, 2H), 1.90 - 1.75 (m, 2H).
[0526] Step 3: 3-(2-methyl-2-nitro-propyl)tetrahydropyran-2-one
[0527]
[0528] A 5000 mL, three-necked round-bottom flask was equipped with a mechanical stirrer, a cooling bath for secondary isolation, a J-Kem temperature probe, an addition funnel, and nitrogen inlets / outlets. The vessel was filled with 2-nitropropane (104.9 g, 1.177 mol) under a nitrogen atmosphere. Stirring was started, and the port temperature was recorded as 19°C. Then, the vessel was filled with 1,8-diazabicyclo[5.4.0]undec-7-ene (22.41 g, 147.2 mmol), which was added all at once as the stock solution, producing a clear pale yellow solution. No exothermic reaction was observed. An addition funnel was filled with a solution of 3-methylenetetrahydropyran-2-one (110 g, 981.0 mmol) in acetonitrile (1100 mL) and added dropwise over 1 hour, which produced a clear pale yellow solution and gradually heated to 24°C. The reaction mixture was stirred continuously at room temperature for 3.5 hours and then concentrated under reduced pressure. The remaining residue was dissolved in dichloromethane (1000 mL) and distributed into a 3:2 mixture of 1 molar citric acid solution and 500 mL of saturated sodium chloride solution. The resulting organic phase was a clear pale blue solution, and the aqueous phase was a slightly turbid and very pale blue solution. The organic layer was removed, and the remaining aqueous layer was extracted with dichloromethane (300 mL). The combined organic layer was washed with a saturated sodium chloride solution (300 mL), dried over sodium sulfate (250 g), and then filtered through a glass Fritt-Buchner funnel. The filtrate was concentrated to a volume of approximately 200 mL under reduced pressure. The clear pale blue dichloromethane solution was methyl Burst The mixture was diluted with γ-butyl ether (1500 mL), and the turbid solution was concentrated to a volume of approximately 200 mL under reduced pressure to obtain a suspension. The mixture was methyl BurstIt was diluted again with β-butyl ether (1500 mL) and concentrated to a volume of approximately 250 mL under reduced pressure. The resulting suspension was left overnight (approximately 12 hours) at room temperature. The solid was collected by vacuum filtration through a glass Fritt Buchner funnel, and the filter cake was cold methyl Burst The material was washed with butyl ether (2 x 150 mL) and then aspirated for 30 minutes. The material was further dried in a vacuum oven at 45°C for 5 hours to obtain the desired product, 3-(2-methyl-2-nitro-propyl)tetrahydropyran-2-one, as a white solid (160 g, 0.795 mol, 81% yield). 1 ¹H NMR (400 MHz, dimethyl sulfoxide-d6) δ 4.34 (ddd, J = 11.1, 9.3, 4.3 Hz, 1H), 4.20 (dt, J = 11.1, 5.1 Hz, 1H), 2.75 - 2.62 (m, 1H), 2.56 (dd, J = 14.9, 5.2 Hz, 1H), 2.01 - 1.89 (m, 2H), 1.89 - 1.67 (m, 2H), 1.55 (d, J = 6.0 Hz, 6H), 1.44 (dddd, J = 12.8, 11.5, 8.1, 6.6 Hz, 1H).
[0529] Step 4: ( S )-3-(2-methyl-2-nitropropyl)tetrahydro-2 H -Preparation of Pyran-2-one
[0530]
[0531] Racemite 3-(2-methyl-2-nitropropyl)tetrahydro-2 H Pyran-2-one was dissolved in 80 g / L + / - 8 g / L (target 80 + / - 2 g / L) of MeOH / ACN 70 / 30 v / v, and separated on the stationary phase Chiralpak AD 20 μm using MeOH / ACN 70 / 30 v / v as the mobile phase. S)-3-(2-methyl-2-nitropropyl)tetrahydro-2 H -Pyran-2-on is peak 2.
[0532] Selective recrystallization of (S)-3-(2-methyl-2-nitropropyl)tetrahydro-2H-pyran-2-one : ( S )-3-(2-methyl-2-nitropropyl)tetrahydro-2 H -Pyran-2-one (9.5 kg, 1.0 equivalent) was stirred in isopropanol (76 L, 8 vol) and then heated to >70°C to dissolve the solid. Then, the mixture was cooled to 20°C over 4-5 hours, the solid was isolated by filtration, the cake was washed with isopropanol (4.75 L, 0.5 vol) and suction dried. The material was dried under vacuum ( S )-3-(2-methyl-2-nitropropyl)tetrahydro-2 H -Pyran-2-one was obtained with a recovery rate of ~90%.
[0533] Step 5: ( S Synthesis of )-3-(3-hydroxypropyl)-5,5-dimethylpyrrolidine-2-one
[0534]
[0535] A suspension of Raney Nickel 2400 (77 wt%, 2.8 kg) was left to precipitate for 2 days. The supernatant was drained and discarded, and the remaining catalyst was loaded into the reactor with water (2.6 kg) and then degassed with N2. In the second reactor, ( S )-3-(2-methyl-2-nitropropyl)tetrahydro-2 HA mixture of -pyran-2-one (13.9 kg) and EtOH (170.8 kg) was heated to 30°C, degassed with N2, and then transferred to a reactor containing Raney nickel. The transfer was completed by rinsing with EtOH (29.8 kg). The mixture was purged three times with nitrogen and three times with hydrogen. The contents of the reactor were heated to 60-65°C and stirred under H2 (4-8 psi) until the reaction was complete (18 hours). The mixture was cooled to 15-20°C, purged three times with nitrogen, and then filtered through a Celite pad (3.0 kg) soaked in EtOH (3.2 kg). The reactor and Celite cake were washed with EtOH (2 × 14.0 kg). The filtrate was distilled to a final volume of approximately 25 L and then heated to 45°C. Then, MTBE (269.4 kg) was charged while maintaining a temperature of 48-50°C, and then distilled under ambient pressure at 48-55°C to a final volume of approximately 30 L. Two additional portions of MTBE (187.4 kg following 269.4 kg) were added sequentially, and then concentrated to a volume of approximately 30 L.
[0536] The contents of the reactor at 40℃ ( S It was seeded with )-3-(3-hydroxypropyl)-5,5-dimethylpyrrolidin-2-one (70.1 g). The seeded crystal slurry was cooled to 15°C over a period of 3.5 hours, stirred for 16.5 hours between 12 and 15°C, and then filtered. Then, the reactor and filter cake were washed with cold (-2 to -10°C) MTBE (2 × 10 kg). The filter cake was dried to constant weight ( S )-3-(3-hydroxypropyl)-5,5-dimethylpyrrolidin-2-one (10.4 kg; 88%) was obtained as a white crystalline solid.
[0537] ( S Recrystallization of )-3-(3-hydroxypropyl)-5,5-dimethylpyrrolidin-2-one: ( SA mixture of )-3-(3-hydroxypropyl)-5,5-dimethylpyrrolidin-2-one (10.3 kg) and DCM (28.2 kg) was stirred and heated to 25°C for 2 hours, then transferred to another reactor through an inline filter (45 µm). The initial reactor was rinsed with DCM (6.8 kg) at 21°C for 10 minutes, then transferred to the reactor through an inline filter. MTBE (38.1 kg) was charged into the solution at 25-30°C, and the mixture was distilled under atmospheric pressure at 35-52°C for a period of 2.5 hours to a final volume of approximately 30 L. MTBE (38.2 kg) was charged into the reactor at 45-50°C. The resulting suspension was distilled under atmospheric pressure at 49-55°C for a period of 3.25 hours to a final volume of approximately 30 L. The contents of the reactor were cooled to 21°C over a period of 2.5 hours and stirred at 20°C for 16 hours. The suspension was filtered. The reactor and filter cake were rinsed with MTBE (7.7 kg, 0.0°C). The filter cake was dried over a period of 2 days. Yield: 9.1 kg (88.3%) of grayish-white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 4.38 (s, 1H), 3.38 (t, J = 6.5 Hz, 2H), 2.37 (qd, J = 9.5, 4.4 Hz, 1H), 2.02 (dd, J = 12.4, 8.6 Hz, 1H), 1.78 - 1.63 (m, 1H), 1.50 - 1.33 (m, 3H), 1.16 (d, J = 17.9 Hz, 7H). ESI-MS m / z calculated value 171.12593, measured value 172.0 [M+1] + . GCMS:100% (AUC). Chiral HPLC: 100% (AUC).
[0538] Step 6: ( S Synthesis of )-3-(5,5-dimethylpyrrolidine-3-yl)propan-1-ol
[0539]
[0540] LiAlH4 pellets (332.5 g, 8.760 mol, 1.50 equivalents) were slowly added to a reactor containing 2-MeTHF (10.00 L, 10 vol) at 30-40°C. Then, the mixture was heated to 75°C. S A mixture of )-3-(3-hydroxypropyl)-5,5-dimethylpyrrolidin-2-one (1,000 g, 5.840 mol, 1.00 equivalent) and 2-MeTHF (10.00 L, 10 vol) was prepared in a separate reactor, heated to 65°C, and then carefully transferred to a reactor containing the LiAlH4 mixture over 2 hours. The mixture was stirred at 70°C until the reaction was complete (18-24 hours), then cooled to 0-10°C. Then, water (400.0 mL, 1 x LiAlH4 wt) was carefully added while maintaining the mixture temperature at <30°C. Then, water (400.0 mL, 1 x LiAlH4 wt) was added following a solution of aqueous 15% NaOH (400.0 mL, 1 x LiAlH4 wt) while maintaining the mixture temperature at <30°C. Then, the resulting mixture was heated to 60°C and maintained at that temperature for at least 30 minutes. The mixture was cooled to 20-30°C, and then Celite (200 g, 20 wt%) was added. Then, the mixture was filtered through a Celite pad. The reactor and filter cake were rinsed with 2-MeTHF (4.0 L, 4.0 vol). The filtrate was concentrated under vacuum to obtain the pyrrolidine compound ( S )-3-(5,5-dimethylpyrrolidin-3-yl)propan-1-ol (872 g; 94.95% yield) was obtained as a clear oil.
[0541] 1 ¹H NMR (400 MHz, dimethyl sulfoxide-d6) δ 3.36 (t, J = 6.3 Hz, 3H), 2.95 (dd, J= 10.6, 7.6 Hz, 1H), 2.40 (dd, J = 10.6, 7.7 Hz, 1H), 2.12 - 1.97 (m, 1H), 1.69 (dd, J = 12.1, 8.2 Hz, 1H), 1.47 - 1.25 (m, 5H), 1.08 (s, 3H), 1.02 (s, 3H).
[0542] Step 7: ( S Synthesis of )-6-bromo-2-(4-(3-hydroxypropyl)-2,2-dimethylpyrrolidine-1-yl)nicotinamide
[0543]
[0544] In 2-methyltetrahydrofuran (23 L) ( S A mixture of )-3-(5,5-dimethylpyrrolidin-3-yl)propan-1-ol (2325 g, 14.8 mol) and 6-bromo-2-fluoropyridine-3-carboxamide (3400 g, 15.5 mol) was stirred, and then potassium carbonate (2650 g, 19.2 mol) and deionized water (7 L) were added. The mixture was stirred at <25°C until the reaction was complete (≥16 hours).
[0545] The aqueous phase was removed, and the upper organic phase was washed with water (7 L) and 2% aqueous sodium chloride (7 L). The organic layer was concentrated to about 19 L under reduced pressure. 2-methyltetrahydrofuran was chased from the mixture by distillation following two sequential additions of acetonitrile (2 x 20 L) and concentration. Acetonitrile (20 L) was added to the remaining solution, and the reaction mixture was heated to 85°C for 2 hours, then cooled to 25°C at a rate of 10°C / hour. The slurry was cooled to 10°C, stirred for 4 hours, and then filtered. The cake was rinsed twice with acetonitrile (2 x 3 L), and the solid was dried under vacuum ( S )-6-bromo-2-(4-(3-hydroxypropyl)-2,2-dimethylpyrrolidin-1-yl)nicotinamide was obtained as a crystalline white solid (3850 g, 73% yield).
[0546] 1H NMR (400 MHz, DMSO-d6) δ 7.78 (s, 1H), 7.39 (s, 1H), 7.34 (dd, J = 7.7, 1.0 Hz, 1H), 6.67 (d, J = 7.6 Hz, 1H), 4.42 (t, J = 5.1 Hz, 1H), 3.39 (q, J = 5.7 Hz, 2H), 3.29 - 3.12 (m, 2H), 2.19 (dt, J = 10.9, 5.8 Hz, 1H), 1.92 (dd, J = 11.9, 5.7 Hz, 1H), 1.53 (s, 3H), 1.50 (s, 3H), 1.48 - 1.29 (m, 5H).
[0547] Step 8: ( S Synthesis of )-6-bromo-2-(4-(3-(1,3-dioxoisoindolin-2-yl)propyl)-2,2-dimethylpyrrolidine-1-yl)nicotinamide
[0548]
[0549] ( S A mixture of )-6-bromo-2-(4-(3-hydroxypropyl)-2,2-dimethylpyrrolidin-1-yl)nicotinamide (2.65 kg, 7.4 mol), 2-methyltetrahydrofuran (16 L), and triethylamine (900 g, 8.88 mol) was stirred at 20°C, and then methanesulfonyl chloride (933 g, 8.14 mol) was added over a period of 2 hours. The mixture was stirred at 20°C until the reaction was complete (typically 16 hours). The resulting mixture was filtered, and the filter cake BurstIt was rinsed with butylmethyl ether (2 x 4 L). The combined filtrate (containing the mesylate intermediate) was transferred to a reactor and diluted with dimethyl sulfoxide (16 L). Phthalimide (1198 g, 8.14 mol) was added to the mixture. The mixture was stirred until a solution was obtained, then potassium carbonate (1023 g, 7.4 mol) was added, and the mixture was stirred until the reaction was complete (2 hours) and heated to 70°C. The mixture was cooled to 20°C, diluted with 2-methyltetrahydrofuran (16 L), and then deionized water (21 L) was added. The phases were separated, and the upper organic phase was washed with deionized water (10 L) and saturated aqueous sodium chloride (2 x 1 L). The organic phase was diluted with toluene (16 L) and concentrated to a volume of approximately 10 L under reduced pressure. The solid was filtered to isolate it, and the filter cake was rinsed with toluene (2 x 2 L). The resulting solid was dried to form the compound ( S )-6-bromo-2-(4-(3-(1,3-dioxoisoindolin-2-yl)propyl)-2,2-dimethylpyrrolidine-1-yl)nicotinamide was obtained as a grayish-white solid (3393 g, 6.99 mol, 94% yield).
[0550] 1 ¹H NMR (400 MHz, DMSO- d 6) δ 7.91 - 7.80 (m, 4H), 7.80 - 7.71 (m, 1H), 7.42 - 7.36 (m, 1H), 7.34 (d, J = 7.7 Hz, 1H), 7.29 - 7.09 (m, 3H), 6.67 (d, J = 7.7 Hz, 1H), 3.59 (t, J = 6.9 Hz, 2H), 3.23 (t, J = 10.4 Hz, 1H), 3.16 (dd, J = 10.2, 7.4 Hz, 1H), 2.30 (s, 2H), 2.28 - 2.13 (m, 1H), 1.90 (dd, J= 12.0, 5.6 Hz, 1H), 1.71 - 1.53 (m, 2H), 1.51 (s, 3H), 1.48 (s, 3H), 1.47 - 1.23 (m, 3H).
[0551] Step 9: Synthesis of Perfluorophenyl 6-Fluorpyridine-2-Sulfonate
[0552]
[0553] Aqueous KHCO3 (approximately 90.30 mL of 20% w / v, 180.4 mmol) was added to a solution of 2,3,4,5,6-pentafluorophenol (33.21 g, 180.4 mmol) in iPrOAc (175 mL). The mixture was stirred at ambient temperature for 10 minutes. Then, a solution of 6-fluoropyridine-2-sulfonyl chloride (35.29 g, 180.4 mmol) in iPrOAc (25 mL) was added while maintaining the temperature below 20°C. The reaction mixture was stirred at ambient temperature for 1 hour to complete the reaction. The aqueous layer was removed, the organic layer was washed with water (50 mL), dried over Na2SO4, and then concentrated by rotary evaporation to remove most of the solvent and precipitate a white solid. Heptane (70 mL) was added, and the slurry was stirred at ambient temperature. The solid was filtered and collected, rinsed with heptane (30 mL), and dried under vacuum to obtain 58.76 g of perfluorophenyl 6-fluoropyridine-2-sulfonate as a white solid. The mother liquor was concentrated by rotary evaporation, then 1 mL (iPrOAc) / 20 mL (heptane) was added and stirred overnight at ambient temperature. The resulting solid was collected and dried overnight in a vacuum oven at ambient temperature under N2 bleed to obtain 0.87 g of secondary product. A total of 59.63 g (96% yield) of perfluorophenyl 6-fluoropyridine-2-sulfonate was obtained. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 8.46 (q, J = 7.7 Hz, 1H), 8.20 (dd, J= 7.5, 2.0 Hz, 1H), 7.84 (dd, J = 8.3, 2.2 Hz, 1H). 19 F NMR (376 MHz, DMSO-d6) δ -64.25 (s, 1F), -152.20 - -152.69 (m, 2F), -154.84 (t, J = 23.3 Hz, 2F), -161.00 - -161.74 (m, 1F).
[0554] Step 10: ( S )-6-bromo-2-(4-(3-(1,3-dioxoisoindoline-2-yl)propyl)-2,2-dimethylpyrrolidine-1-yl)- N Synthesis of ((6-fluoropyridine-2-yl)sulfonyl)nicotinamide
[0555]
[0556] While maintaining the internal temperature below -2℃, lithium Burst - A solution of butoxide (1,905.13 g, 2.20 equivalents, 20% w / w in THF) in 2-MeTHF (10.5 L, 10.0 vol) ( S)-6-bromo-2-(4-(3-(1,3-dioxoisoindolin-2-yl)propyl)-2,2-dimethylpyrrolidin-1-yl)nicotinamide (1,050 g, 1.00 equivalents) and perfluorophenyl 6-fluoropyridine-2-sulfonate (890.93 g, 1.20 equivalents) were added to a mixture. The mixture was stirred at -10°C until the reaction was complete (typically 0.5 hours). A solution of aqueous HCl (5.25 L, 5 vol, 1 N) was added while maintaining an internal temperature < 20°C. Then, 2-MeTHF (5.0 L, 5 vol) was added to the reactor at ambient temperature, and the phases were separated. The lower aqueous layer was discarded. The organic phase was washed with water (5 vol) and then concentrated to 5 volumes under vacuum while maintaining a temperature below 50°C. 2-MeTHF (10.0 L, 10 vol) was added, and the mixture was concentrated back to 5 volumes. 2-MeTHF (5 vol) was added, and the heterogeneous mixture was heated to 70°C while stirring until complete dissolution occurred. Then, the mixture was cooled linearly to 45°C over 6 hours and held at 45°C for 6 hours. Then, the mixture was cooled to 25°C over 2 hours, and then heptane (10.0 L, 10 vol) was added to the mixture over 3 hours. The mixture was discharged from the reactor, and the solid was isolated. Then, the reactor and filter cake were washed twice with a mixture of 2-MeTHF (2.0 L, 2 vol) and heptane (2.0 L, 2 vol). The solid was dried under vacuum at 45°C ( S )-6-bromo-2-(4-(3-(1,3-dioxoisoindoline-2-yl)propyl)-2,2-dimethylpyrrolidine-1-yl)- N -((6-fluoropyridine-2-yl)sulfonyl)nicotinamide was obtained. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 13.05 (s, 1H), 8.37 (q, J = 7.8 Hz, 1H), 8.11 (dd,J = 7.4, 1.9 Hz, 1H), 7.95 - 7.88 (m, 2H), 7.88 - 7.81 (m, 2H), 7.59 (dd, J = 8.1, 2.4 Hz, 2H), 6.78 (d, J = 7.9 Hz, 1H), 3.59 (t, J = 6.8 Hz, 2H), 2.45 (dd, J = 8.8, 3.9 Hz, 2H), 2.17 (s, 1H), 1.87 (dd, J = 11.9, 5.5 Hz, 1H), 1.56 (dddd, J = 22.3, 16.7, 8.9, 4.1 Hz, 2H), 1.47 (s, 3H), 1.44 (s, 3H), 1.35 (t, J = 12.1 Hz, 1H), 1.21 (ddd, J = 13.3, 10.5, 5.4 Hz, 1H), 1.00 (dtd, J = 14.1, 9.4, 5.7 Hz, 1H).
[0557] Step 11: ( S Synthesis of )-2-((3-(1-(6-bromo-3-(((6-fluoropyridine-2-yl)sulfonyl)carbamoyl)pyridine-2-yl)-5,5-dimethylpyrrolidine-3-yl)propyl)carbamoyl)benzoic acid
[0558]
[0559] From the previous step ( SA reaction solution containing )-6-bromo-2-(4-(3-(1,3-dioxoisoindolin-2-yl)propyl)-2,2-dimethylpyrrolidine-1-yl)-N-((6-fluoropyridine-2-yl)sulfonyl)nicotinamide was cooled and maintained below 10°C, while a solution of LiOH·H2O (284 g, 6.77 mol; 3 equivalents) in water (2.19 L; 2 volume equivalents) was added. The two-phase mixture was stirred at 5–15°C until the reaction was complete (approx. 2 hours). While maintaining the reaction temperature below 10°C, 2 M HCl (5.64 L, 11.3 mol; 5 equivalents) was added dropwise over approximately 1 hour. The pH of the aqueous phase was approximately 2. After separating the phases, the organic phase was concentrated to a minimum volume to remove most of the 2-MeTHF (40°C / 150 - 70 torr). The reaction mixture was then proceeded to the next step without any additional treatment.
[0560] Step 12: ( S )-2-(4-(3-aminopropyl)-2,2-dimethylpyrrolidine-1-yl)-6-bromo- N Synthesis of ((6-fluoropyridine-2-yl)sulfonyl)nicotinamide
[0561]
[0562] From the previous step ( S A concentrate containing )-2-((3-(1-(6-bromo-3-(((6-fluoropyridine-2-yl)sulfonyl)carbamoyl)pyridine-2-yl)-5,5-dimethylpyrrolidine-3-yl)propyl)carbamoyl)benzoic acid was diluted with CH3CN (6.56 L; 6 volume equivalents) and water (3.83 L; 2 volume equivalents), then oxalic acid (508 g, 5.64 mol; 2.5 equivalents) was added, and the resulting solution was heated at 60°C until the reaction was complete (about at least 4 hours). The solution was cooled to 0-10°C, and then a solution of K2CO3 (2.18 kg, 15.8 mol; 7 equivalents) in water (3.83 L; 3.5 volume equivalents) was added dropwise while maintaining the reaction temperature below 10°C. The solid was collected by filtration. Add the wet filter cake to water (2 x 2.2 L; 2 volume equivalents).i- Wash sequentially with PrOH (2 x 600 mL; 0.5 volume equivalents), air-dry by suction, and vacuum-dry (50℃ / 30 torr) ( S )-2-(4-(3-aminopropyl)-2,2-dimethylpyrrolidine-1-yl)-6-bromo- N -((6-fluoropyridine-2-yl)sulfonyl)nicotinamide (959 g; 83% during 3 steps; >98% AUC) was obtained as a fine white powder. 1 H NMR (400 MHz, DMSO-d6) δ 8.09 (q, J = 7.9 Hz, 1H), 7.83 (dd, J = 7.5, 2.2 Hz, 1H), 7.67 (s, 3H), 7.39 (d, J = 7.6 Hz, 1H), 7.23 (dd, J = 8.2, 2.4 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 3.20 - 2.99 (m, 2H), 2.81 (td, J = 7.2, 4.7 Hz, 2H), 2.08 (dh, J = 15.3, 7.0 Hz, 1H), 1.84 (dd, J = 11.8, 5.7 Hz, 1H), 1.54 (q, J = 7.6 Hz, 2H), 1.48 (s, 3H), 1.47 (s, 3H), 1.37 (t, J = 11.9 Hz, 1H), 1.26 (ddd, J = 29.1, 13.8, 7.4 Hz, 2H).
[0563] Step 13: (14 S )-8-bromo-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 Synthesis of ]tetracosa-1(23),5,7,9,19,21-hexane-2,2,4-trione
[0564]
[0565] In DMSO (7.60 L; 8 volume equivalents) ( S )-2-(4-(3-aminopropyl)-2,2-dimethylpyrrolidine-1-yl)-6-bromo- N A mixture of -((6-fluoropyridine-2-yl)sulfonyl)nicotinamide (950 g, 1.85 mol) and Na2CO3 (392 g, 3.69 mol; 2 equivalents) was heated at 85°C until the reaction was complete (~6 hours). The suspension was cooled to <15°C and diluted with MeTHF (19.0 L; 20 volume equivalents). Water (13.3 L) was slowly added while maintaining the reaction temperature <15°C. 2 M HCl (4.62 L, 9.24 mol; 5 equivalents) was added while maintaining the reaction temperature <15°C (pH ~2). The phases were separated, and the organic phase was washed twice with water (9.50 L; 10 volume equivalents) containing NaCl (190 g; 2 wt%). The organic phase was concentrated to a minimum volume (45°C / 180 torr) i- MeTHF was removed by chasing with PrOAc (2-3 x 500 mL). On the concentrate i- PrOAc (3,800 L; 4 volume equivalents) was refilled and stirred at 45°C until crystallization occurred. (If necessary, to the mixture (14 S )-8-bromo-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 ]tetracosa-1(23),5,7,9,19,21-hexaene-2,2,4-trione can be seeded). The suspension was aged with stirring for at least 30 minutes and then cooled to 20°C. After aging at 20°C for at least 2 hours, the solid was filtered and collected. The filter cake was 1:1 i- Wash with PrOAc / MTBE (500-mL), air-dry by suction, and vacuum-dry (40 - 55℃ / <100 torr / N2 bleed) (14 S)-8-bromo-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 ]tetracosa-1(23),5,7,9,19,21-hexane-2,2,4-trione ·0.8 i- PrOAc (830 g; i- PrOAc solvate correction (78% yield) was obtained as a pale yellow white powder.
[0566] The filtrate was concentrated to a total volume of approximately 400 mL to obtain the secondary product. Then, the mixture was seeded and aged at 15–20°C. The solid was collected by filtration. The filter-cake was 1:1 i- Washed sequentially with PrOAc / MTBE (200 mL) and MTBE (100 mL), air-dried by suction, and vacuum-dried (55℃ / <100 torr / N2 bleed) (14 S )-8-bromo-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 ]tetracosa-1(23),5,7,9,19,21-hexaen-2,2,4-trion·0.67 i- PrOAc (113 g; 11% corrected yield) was obtained as a pale yellow solid. 1 ¹H NMR (400 MHz, chloroform- d ) δ 9.13 (s, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.54 (dd, J = 8.4, 7.3 Hz, 1H), 7.43 (d, J = 7.3 Hz, 1H), 6.79 (d, J = 7.9 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 4.99 (hept, J = 6.3 Hz, 1H), 4.57 (d, J= 8.8 Hz, 1H), 4.02 - 3.85 (m, 1H), 3.27 - 3.09 (m, 2H), 2.96 (t, J = 10.2 Hz, 1H), 2.35 (p, J = 9.5 Hz, 1H), 2.02 (s, 3H), 1.95 (dd, J = 12.1, 6.7 Hz, 1H), 1.72 - 1.59 (m, 6H), 1.58 (s, 3H), 1.55 (s, 3H), 1.43 (d, J = 40.1 Hz, 1H), 1.23 (d, J = 6.3 Hz, 5H).
[0567] Part B. Synthesis of Banzakauther glass form A
[0568] The reactor was equipped with an overhead stirrer, a reflux condenser, an N2 bubble line and outlet, and a temperature probe. (14 S )-8-bromo-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 ]Tetracosa-1(23),5,7,9,19,21-hexane-2,2,4-trione (containing IPAc 86% w / w 120 g [103.2 g (14 S )-8-bromo-12,12-dimethyl-2λ 6 -thia-3,9,11,18,23-pentazatetracyclo[17.3.1.1 11,14 .0 5,10 ]tetracosa-1(23),5,7,9,19,21-hexane-2,2,4-trione], 0.21 mol, 1 equivalent), 3-(2-(disspiro[2.0.2 4 .1 3 ]heptane-7-yl)ethoxy)-1 HA mixture of pyrazole (42.6 g, 0.21 mol, 1 equivalent), 325 mesh K2CO3 (63.4 g, 0.46 mol, 2.2 equivalents), CuI (3.3 g, 17.2 mmol, 0.083 equivalents), and BuOAc (740 mL) was charged into a reactor. The mixture was stirred at ambient temperature. Then, DMF (300 mL, 2.9 vol) and N , N'-dimethylcyclohexane-1,2-diamine (14.6 g or 16.2 ml, 0.1 mol, 0.49 equivalents) was charged into a reactor, and the mixture was purged by three N2 / vacuum / N2 cycles. Then, the mixture was heated to 120°C for 4 hours and then cooled to ambient temperature. 10% aqueous w / v oxalic acid (860 mL, 0.96 mol, 4.6 equivalents) was added dropwise, and the mixture was stirred for at least 1 hour. Then, the mixture was filtered to remove the suspended solid. The removed solid was washed with (2 x 120 mL). The layer from the filtrate was separated. The organic layer was washed with 8% aqueous w / v trisodium citrate (600 mL). Brine was added as needed to aid phase separation. The organic layer was washed with 1:1 v / v water / brine (400 mL). The organic layer was filtered through a Celite pad. The filter pad was washed with IPAc (150 mL). The filtrate was concentrated, then 800 mL of 1-PrOH (7.8 vol) was added and the mixture was concentrated. This step was repeated once more. Toluene (800 mL) was added and the mixture was concentrated. This step was repeated once more to obtain a thick slurry. The crude mixture was concentrated to a volume of 300 mL (2.9 vol) of toluene. After stirring the slurry overnight, the solid was filtered and collected by washing the solid with toluene (2 x 100 mL, 0.97 vol). The solid was dried under vacuum with nitrogen bleed at 50°C until the loss on drying was 1.0% or less to obtain a white / grayish-white solid (107.0 g, 83%, 94.5% (AUC) HPLC purity).
[0569] Recrystallization: Banjacafter form A [22.2 g, 94.6% (AUC)] Banjacafter form A was suspended in toluene (440 mL, 20 vol based on Banjacafter form A), and the mixture was heated under reflux. After maintaining under reflux for 2 hours, the mixture was cooled to ambient temperature over 8 hours. After stirring overnight at ambient temperature, the solid was filtered and collected by washing the solid with toluene (40 mL, 1.8 vol). The solid was dried under vacuum with nitrogen bleed at 50°C until the loss on drying was 1.0% or less, yielding Banjacafter form A as a white / grayish-white solid (18.8 g, 84%, 96.8% (AUC) HPLC purity).
[0570] Second recrystallization: Banja-kafter form A [17.5 g, 97.0% (AUC) Banja-kafter form A] was suspended in toluene (350 mL, 20 vol based on Banja-kafter form A), and the mixture was heated under reflux. After maintaining under reflux for at least 2 hours, the mixture was cooled to ambient temperature over 8 hours. After stirring overnight at ambient temperature, the solid was filtered and collected by washing the solid with toluene (40 mL, 1.8 vol). The solid was dried under vacuum with nitrogen bleed at 50°C until the loss on drying was 1.0% or less, yielding Banja-kafter form A (glass form) as a white / grayish-white solid (15.7 g, 89%, 98.4% (AUC) HPLC purity).
[0571] Part C. Synthesis of Banjakaftor Calcium Salt Hydrate Form A
[0572] Banjakafter calcium salt hydrate form A was prepared by packing 0.2 mmol of banjakafter glass form A and 0.1 mmol of dry Ca(OMe)2 powder with ~45 mg / mL IPA, spiking with ~10% water, and heating to 70°C. Initially, all solids dissolved. After 5 minutes, a white solid precipitated. The resulting slurry was stirred at room temperature for 4 days. The solids were isolated as banjakafter calcium salt hydrate form A by vacuum filtration and dried overnight at 40°C under vacuum (~78% isolated yield).
[0573] An alternative method for preparing Banjakafter calcium salt hydrate form A utilized 10 g of Banjakafter glass form A filled with 63 mL IPA and 7 mL water. The slurry was heated to 55–65°C. The mixture was filled with 1.1 equivalents of NaOH. The mixture was stirred until the solution became homogeneous. Then, the solution was cooled to 25°C and seeded with 0.1 g of Banjakafter sodium salt hydrate form A. The slurry was stirred for 18 hours. Then, the solution was heated to 45°C. 0.1 g of Banjakafter calcium salt hydrate form A was seeded into the slurry. A solution of 0.55 equivalents of CaCl2, 9 mL IPA, and 1 mL water was added over a period of 5 hours. The resulting slurry was stirred for 2 hours. The slurry was cooled to 20°C over a period of 5 hours. The resulting solid was collected by vacuum filtration, and the resulting wet cake was washed with 50 mL of water. The washed wet cake was air-dried for 1 hour. The air-dried wet cake was transferred to a vacuum oven at 45°C with a small amount of nitrogen bleed and dried for 20 hours to obtain crystalline banjacafter calcium salt hydrate form A (8.5 g, 82% isolated yield).
[0574] Part D. Synthesis of Banjakaftor Calcium Salt Hydrate Form D
[0575] Approximately 25 mg of banjakarftor calcium salt hydrate form A was packed with 0.5 mL of EtOH:water 67:33 w / w. The slurry was heated to 65°C for 8 days. The resulting solid collected by vacuum filtration was banjakarftor calcium salt hydrate form D.
[0576] Alternatively, Banjakafter calcium salt hydrate form D was prepared from 89 g of Banjakafter sodium hydrate form A, which was filled with 1080 mL IPA and 120 mL water. The slurry was heated to 55–65°C. The slurry was filled with 18 g of Banjakafter calcium salt hydrate form D seeds. The slurry was wet-milled while adding a solution of 0.55 equivalents of CaCl2, 81 mL IPA, and 9 mL water over a period of 5 hours. The wet mill was operated until it was confirmed by X-ray powder diffraction that the entire slurry was Banjakafter calcium salt hydrate form D. The resulting solid was collected by vacuum filtration, and the wet cake was washed with 350 mL of water. The washed wet cake was air-dried for 1 hour. The air-dried wet cake was transferred to a vacuum oven at 45°C with a small amount of nitrogen bleed and dried for 20 hours to obtain crystalline banjacafter calcium salt hydrate form D (83.15 g, 90.6% isolated yield).
[0577] Example 2: ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H Synthesis of -Indole-5-1)Cyclopropanecarboxamide (Tezacarfter)
[0578] The synthesis of tezakarfter is described in U.S. Patent Publication US 2009 / 0131492, which is incorporated herein by reference for the purposes of this disclosure. The production of solid dispersions of tezakarfter is described in International Patent Publications WO 2011 / 119984 and WO 2015 / 160787, the contents of which are incorporated herein by reference in their entirety.
[0579]
[0580] Step 1: ( R )-Benzyl 2-(1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-5-nitro-1 H -indole-2-yl)-2-methylpropanoate and (( S )-2,2-dimethyl-1,3-dioxolane-4-yl)methyl 2-(1-((( R )-2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-5-nitro-1 H -indole-2-yl)-2-methylpropanoate
[0581] Cesium carbonate (8.23 g, 25.3 mmol) in DMF ( N , N Benzyl 2-(6-fluoro-5-nitro-1 in dimethylformamide) (17 mL) H It was added to a mixture of (S)-(2,2-dimethyl-1,3-dioxolane-4-yl)methyl 4-methylbenzenesulfonate (7.23 g, 25.3 mmol) and (Indole-2-yl)-2-methylpropanoate (3.0 g, 8.4 mmol). The reaction mixture was stirred at 80°C for 46 hours under a nitrogen atmosphere. Then, the mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined ethyl acetate layer was washed with brine, dried over MgSO4, filtered, and concentrated. The crude product, a viscous brown oil containing both of the products presented above, was used directly in the next step without further purification. ( R )-Benzyl 2-(1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-5-nitro-1 H -indole-2-yl)-2-methylpropanoate, ESI-MS m / z Calculated value 470.2, measured value 471.5 (M+1) + . Duration of stay 2.20 minutes. (( S )-2,2-dimethyl-1,3-dioxolane-4-yl)methyl 2-(1-((( R )-2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-5-nitro-1 H -indole-2-yl)-2-methylpropanoate, ESI-MS m / zCalculated value 494.5, Measured value 495.7 (M+1) + . Duration of stay 2.01 minutes.
[0582] Step 2: ( R )-2-(1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-5-nitro-1 H -indole-2-yl)-2-methylpropane-1-ol
[0583] The crude reaction mixture obtained in Step 1 was dissolved in THF (42 mL) and cooled in an ice bath. LiAlH4 (16.8 mL of 1 M solution, 16.8 mmol) was added dropwise. After the addition was complete, the mixture was stirred for an additional 5 minutes. The reaction was quenched by adding water (1 mL), 15% NaOH solution (1 mL), and subsequently water (3 mL). The mixture was filtered over Celite, and the solid was washed with THF and ethyl acetate. The filtrate was concentrated and purified by column chromatography (30-60% ethyl acetate-hexane) ( R )-2-(1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-5-nitro-1 H -indole-2-yl)-2-methylpropane-1-ol was obtained as a brown oil (2.68 g, 87% over two steps). ESI-MS m / z Calculated value 366.4, measured value 367.3 (M+1) + . Duration of stay 1.68 minutes. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 8.34 (d, J = 7.6 Hz, 1H), 7.65 (d, J = 13.4 Hz, 1H), 6.57 (s, 1H), 4.94 (t, J= 5.4 Hz, 1H), 4.64 - 4.60 (m, 1H), 4.52 - 4.42 (m, 2H), 4.16 - 4.14 (m, 1H), 3.76 - 3.74 (m, 1H), 3.63 - 3.53 (m, 2H), 1.42 (s, 3H), 1.38 - 1.36 (m, 6H) and 1.19 (s, 3H) ppm. (DMSO is dimethyl sulfoxide).
[0584] Step 3: ( R )-2-(5-amino-1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-1 H -indole-2-yl)-2-methylpropane-1-ol
[0585] ( R )-2-(1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-5-nitro-1 H -indole-2-yl)-2-methylpropan-1-ol (2.5 g, 6.82 mmol) was dissolved in ethanol (70 mL), and the reaction mixture was flushed with N2. Then, Pd-C (250 mg, 5% wt) was added. The reaction mixture was flushed again with nitrogen and stirred under H2 (atm). After 2.5 hours, only partial conversion to the product was observed by LCMS. The reaction mixture was filtered through Celite and concentrated. The residue was applied again under the above conditions. After 2 hours, LCMS indicated complete conversion to the product. The reaction mixture was filtered through Celite. The filtrate was concentrated to obtain the product (1.82 g, 79%). ESI-MS m / z Calculated value 336.2, measured value 337.5 (M+1) + . Duration of stay 0.86 minutes. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 7.17 (d, J = 12.6 Hz, 1H), 6.76 (d, J = 9.0 Hz, 1H), 6.03 (s, 1H), 4.79 - 4.76 (m, 1H), 4.46 (s, 2H), 4.37 - 4.31 (m, 3H), 4.06 (dd,J = 6.1, 8.3 Hz, 1H), 3.70 - 3.67 (m, 1H), 3.55 - 3.52 (m, 2H), 1.41 (s, 3H), 1.32 (s, 6H) and 1.21 (s, 3H) ppm.
[0586] Step 4: ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -Indole-5-day)Cyclopropanecarboxamide
[0587] DMF (3 drops) 1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (1.87 g, 7.7 mmol) and thionyl chloride (1.30 mL, 17.9 mmol) were added to a stirred mixture. After 1 hour, a clear solution was formed. The solution was concentrated under vacuum, then toluene (3 mL) was added, and the mixture was concentrated again. The toluene step was repeated once more, and the residue was placed under high vacuum for 10 minutes. Then, the acid chloride was dissolved in dichloromethane (10 mL), and in dichloromethane (45 mL) ( R )-2-(5-amino-1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-1 H It was added to a mixture of -indole-2-yl)-2-methylpropan-1-ol (1.8 g, 5.4 mmol) and triethylamine (2.24 mL, 16.1 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was washed with 1N HCl solution, saturated NaHCO3 solution, and brine, dried over MgSO4, and concentrated to obtain the product (3 g, 100%). ESI-MS m / z Calculated value 560.6, measured value 561.7 (M+1) + . Duration of stay 2.05 minutes. 1 ¹H NMR (400 MHz, DMSO- d6) δ 8.31 (s, 1H), 7.53 (s, 1H), 7.42 - 7.40 (m, 2H), 7.34 - 7.30 (m, 3H), 6.24 (s, 1H), 4.51 - 4.48 (m, 1H), 4.39 - 4.34 (m,2H), 4.08 (dd, J = 6.0, 8.3 Hz, 1H), 3.69 (t, J = 7.6 Hz, 1H), 3.58 - 3.51 (m, 2H), 1.48 - 1.45 (m, 2H), 1.39 (s, 3H), 1.34 - 1.33 (m, 6H), 1.18 (s, 3H) and 1.14 - 1.12 (m, 2H) ppm.
[0588] Step 5: ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -Indole-5-day)Cyclopropanecarboxamide (Tezacarfter)
[0589] ( R )-1-(2,2-difluorobenzo[ d ][1,3]dioxol-5-il)- N -(1-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-6-fluoro-2-(1-hydroxy-2-methylpropane-2-yl)-1 H -indole-5-yl)cyclopropane carboxamide (3.0 g, 5.4 mmol) was dissolved in methanol (52 mL). Water (5.2 mL) was added, followed by the addition of p-TsOH·H2O (p-toluenesulfonic acid hydrate) (204 mg, 1.1 mmol). The reaction mixture was heated at 80°C for 45 minutes. The solution was concentrated and then partitioned between ethyl acetate and a saturated NaHCO3 solution. The ethyl acetate layer was dried and concentrated over MgSO4. The residue was purified by column chromatography (50-100% ethyl acetate-hexane) to obtain the product (1.3 g, 47%, ee >98% based on SFC). ESI-MS m / zCalculated value 520.5, measured value 521.7 (M+1) + . Duration of stay 1.69 minutes. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 8.31 (s, 1H), 7.53 (s, 1H), 7.42 - 7.38 (m, 2H), 7.33 - 7.30 (m, 2H), 6.22 (s, 1H), 5.01 (d, J = 5.2 Hz, 1H), 4.90 (t, J = 5.5 Hz, 1H), 4.75 (t, J = 5.8 Hz, 1H), 4.40 (dd, J = 2.6, 15.1 Hz, 1H), 4.10 (dd, J = 8.7, 15.1 Hz, 1H), 3.90 (s, 1H), 3.65 - 3.54 (m, 2H), 3.48 - 3.33 (m, 2H), 1.48 - 1.45 (m, 2H), 1.35 (s, 3H), 1.32 (s, 3H) and 1.14 - 1.11 (m, 2H) ppm.
[0590] Example 3: Preparation of a solid dispersion of amorphous Tejakafter
[0591] A solvent system of DCM and MeOH was formulated in a suitably sized vessel equipped with a magnetic stirrer and a stirring plate at a ratio of 80 wt% DCM to 20 wt% MeOH. To this solvent system, a hypromellose polymer (HPMC, Grade E15) and tezakarfter were added at a ratio of 20 wt% hypromellose to 80 wt% tezakarfter. The resulting mixture contained 12.5 wt% solid. The actual amounts of ingredients and solvents used to produce this mixture are listed in the table below:
[0592] Solid spray dispersion components for amorphous Tejacarfter:
[0593]
[0594] The mixture was mixed until substantially homogeneous and all components were substantially dissolved.
[0595] Anhydro MS-35 spray dryer, equipped with a 0.8 mm nozzle (Schlick Series 970 / 0 S4) for two-fluid spraying, was used in a normal spray drying mode according to the spray drying process parameters listed in the table below.
[0596] Process parameters for manufacturing a solid spray dispersion of amorphous Tejacarfter:
[0597]
[0598] A high-efficiency cyclone separated the wet product from the spray gas and solvent vapor. The wet product was transferred to a tray and dried in a vacuum dryer, thereby reducing the residual solvent to less than 3000 ppm for MeOH and less than 600 ppm for DCM, and producing a dry dispersion of amorphous tejacarfter containing <0.02% MeOH and <0.06% DCM.
[0599] Example 4: N -(2-( Burst -butyl)-5-hydroxy-4-(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3-d 6 Synthesis of )phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Dutivacarfter)
[0600] The synthesis of duty-free carpenter is described in PCT Publication No. WO 2019 / 109021 and U.S. Patent 9,512,079, each of which is incorporated herein by reference.
[0601] Synthesis of Duty Bar Carfter
[0602]
[0603] 4-( Burst -butyl)phen-2,6-d 2 Synthesis procedure of -ol-d
[0604]
[0605] 4- in a 5 L round-bottom flask equipped with an overhead stirrer Burst β-butylphenol (14, 503.2 g), K2CO3 (46.3 g), D2O (1949 g, 1761 mL, 3.5 vol), and MeOD (409 g, 503 mL, 1.0 vol) were charged. The mixture was heated under reflux in a nitrogen atmosphere. The reaction mixture was aged under reflux for 16 hours. The reaction mixture was cooled to room temperature and sampled for conversion (%D incorporation rate). The reaction mixture was cooled to 5°C, and 35% DCI solution (90 g, 71.2 mL) was added. The reaction mixture was aged at 5°C for 2 hours. The resulting slurry was filtered, and the cake was washed with D2O (836 g, 755 mL, 1.5 vol). This process was repeated until the target %D incorporation rate was met (typically, two exchanges are required). The wet cake was dried in a vacuum oven with nitrogen bleed at 40°C until a constant weight was obtained. 4-( Burst -butyl)phen-2,6- d The yield of 2-ol-d (19) is 506 g of white solid (98%) with 99.6% purity and 99.3% %D incorporation.
[0606] 4-( Burst -butyl)-2-(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3- d 6 )pen-6-d-all-d and 4-( Burst -butyl)-2,6-bis(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3-d 6 Synthesis procedure of phenol-d
[0607]
[0608] 4-( Burst -butyl)phen-2,6- d 2-ol-d (101.8 g, 0.66 mol, 1.0 equivalent) was dissolved in DCM (400 mL) in a 2 L reactor. t -butanol-d 10(43.0 g, 0.51 mol, 0.77 equivalents) was dissolved in DCM (100 mL) in a 250 mL flask. Burst A solution of -butanol-d6 was charged into a 2 L reactor at room temperature. The reaction mixture was cooled to -5°C. D2SO4 (51.1 g, 0.51 mol, 0.77 equivalents) was added dropwise through an addition funnel while maintaining a temperature range of -4 to -2°C. The reaction mixture was stirred at -2°C for 3–4 hours. Upon complete conversion, the reaction mixture was quenched by adding water (28 mL) and heated to 18–20°C. The bottom aqueous layer was drained and discarded. The DCM layer was treated with a saturated aqueous NaHCO3 solution (approximately 200 mL) to adjust the pH to 6–8. A saturated NaCl solution (400 mL) was added to the mixture. The resulting solution was stirred for 5 minutes and allowed to stand for 5 minutes. The bottom DCM layer was drained into a 1 L flask. The aqueous layer was discarded. The DCM solution was concentrated to a minimum volume, and n-heptane (200 mL) was added. The solution was concentrated to a minimum volume, and n-heptane was added to a final volume of 800 mL. 600 mL (6 vol) of 0.5 N NaOH solution was added to the reactor, the resulting mixture was stirred for 5 minutes, and allowed to stand for at least 5 minutes. The aqueous layer was drained and discarded. 300 mL (3 vol) of 1.0 N NaOH solution was added to the reactor, the resulting mixture was stirred for 5 minutes, and allowed to stand for at least 5 minutes. The aqueous layer was drained and discarded. 300 mL (3 vol) of 1.0 N NaOH solution was added to the reactor, the resulting mixture was stirred for 5 minutes, and allowed to stand for at least 5 minutes. The aqueous layer was drained and discarded. The remaining n-heptane solution was concentrated and dried to obtain the desired product, 4-( Burst -butyl)-2-(2-(methyl- d 3)Propane-2-yl-1,1,1,3,3,3- d6) phen-6-d-ol-d (18) was obtained as a clear oil, 104.5 g, and the process was carried out to the next step without further purification.
[0609] 2-Bromo-4-( Burst -butyl)-6-(2-(methyl-d 3 )propane-2-yl- 1,1,1,3,3,3-d 6 Synthesis procedure of phenol
[0610]
[0611] 4-( Burst -butyl)-2-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3- d 6) Phen-6-d-ol-d (100 g, 0.462 mol, 1.0 equivalent) was dissolved in DCM (800 mL, 7 vol) in a 2 L reactor, and the solution was stirred. The batch was cooled to 0 ± 3 ℃. To the batch NBromosuccinimide (84.4 g, 0.462 mol, 1.0 equivalent) was divided into portions over 30 minutes. The batch was stirred at 0 ± 2°C for at least 30 minutes. Then, the batch was heated to 20 ± 2°C over a period of 2 hours and stirred at 20 ± 2°C for at least 12 hours. Upon complete conversion, a saturated aqueous NaHCO3 solution (500 mL, 5 vol) was added, and the batch was stirred for at least 10 minutes. Stirring was stopped to allow the phases to separate for at least 5 minutes, the DCM layer was drained, and the aqueous layer was subsequently removed. The DCM layer was refilled into the container. A saturated aqueous NaHCO3 bicarbonate solution (500 mL, 5 vol) was added to the batch, and the batch was stirred for at least 10 minutes. Stirring was stopped to allow the phases to separate for at least 5 minutes, the DCM layer was drained, and the aqueous layer was subsequently removed. The DCM layer was refilled into the container and diluted with additional DCM (300 mL, 3 vol). The batch was distilled (300 mL removed) and confirmed to be dry by KF. The resulting clear yellow solution of 17 was used in the next step without further purification.
[0612] 2-Bromo-4-( Burst -butyl)-6-(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3-d 6 Synthesis procedure of phenylmethyl carbonate
[0613]
[0614] 4-( in a clean reactor BurstA DCM solution of -butyl)-2-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phen-6-d-ol-d (136 g, 0.462 mol, 1.0 equivalent) was filled, followed by the filling of additional DCM (130 mL, 1 vol) and the solution was stirred. 4-(dimethylamino)pyridine (2.8 g, 0.023 mol, 0.05 equivalent) and triethylamine (70.1 g, 0.693 mol, 1.5 equivalent) were filled into the batch. The batch was cooled to 0 ± 3°C. While maintaining the batch temperature < 5°C, methyl chloroformate (48.0 g, 0.508 mol, 1.1 equivalent) was added dropwise to the batch over 40 minutes. The batch was stirred at 3 ± 2°C for at least 30 minutes, then heated to 20 ± 2°C over a period of 1 hour. Upon complete conversion, 1 N HCl (400 mL, 3 vol) was added. The batch was stirred for at least 10 minutes, then the layers were separated for at least 5 minutes. After draining the bottom organic layer, the aqueous layer (first aqueous layer) was drained. The organic layer was refilled into the reactor with 1 N HCl solution (400 mL, 3 vol). The batch was stirred for at least 10 minutes, then the layers were separated for at least 5 minutes. The bottom organic layer was drained. The first aqueous layer was charged into the reactor with DCM (300 mL, 2.2 vol). The batch was stirred for at least 10 minutes, then the layers were separated for at least 5 minutes. The bottom organic layer was drained and combined with the first organic layer, then the aqueous layer was removed. The contents of both organic layers were filled into a container. Water (500 mL, 3.7 vol) was filled into the reactor. The batch was stirred for at least 10 minutes, and then the layers were separated for at least 5 minutes. After draining the bottom organic layer, the aqueous layer was drained. The organic layer was refilled into the reactor with DCM (400 mL, 3 vol). The batch was distilled to remove 800 mL, and the dry state was confirmed by KF.The generated transparent yellow solution of 16 was proceeded directly to the next step without further purification.
[0615] 2-Bromo-4-( Burst -butyl)-6-(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3-d 6 Synthesis procedure of )-3-nitrophenyl methyl carbonate
[0616]
[0617] 2-bromo-4-( in the reactor Burst -butyl)-6-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phenylmethyl carbonate was added, and the solution was cooled to 0°C. Sulfuric acid (4.9 equivalents) and nitric acid (100%, 2.0 equivalents) were added while maintaining the temperature below 5°C. The reaction mixture was stirred at 0°C for 2 hours until complete conversion was achieved. Then, the reaction mixture was quenched with water (8.8 vol) and diluted with DCM (1.7 vol). The layers were separated, and the upper aqueous layer was extracted with DCM (2.8 vol). After separating the layers, the organic layer was combined, returned to the reactor, and washed with sodium bicarbonate (7.4% w / w, 6.8 vol). After separating the layers, the organic layer was returned to the reactor and washed with sodium chloride (23% w / w, 3.8 vol). After separating the layers, the organic layer was returned to the reactor and concentrated to a minimum volume. After adding methanol (1.2 vol), it was concentrated to a minimum volume. After adding methanol (1.2 vol), it was concentrated to a minimum volume. After adding methanol (1.7 vol), the slurry was refluxed for 30 minutes, and then slowly cooled to 5°C over 4 hours. The solid product (15) was filtered, and the cake was washed with cold methanol (1.0 vol). Solid 2-bromo-4-( Burst-butyl)-6-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)-3-nitrophenyl ethyl carbonate (15) was dried under vacuum at 40-50°C to obtain a grayish-white solid, 99.9% purity and 99% D incorporation rate.
[0618] 5-amino-4-( Burst -butyl)-2-(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3-d 6 Synthesis procedure of phenylmethyl carbonate
[0619]
[0620] 5% Pd / C (50-65 wt% wet, JM type 37) at 5 wt% was charged into the reactor. (4.0 vol) Methanol was charged. The system was closed. N₂ at 2.0 Bar 2(g) Purged with. H at 2.0 Bar 2(g) It was activated with. H in the container at 25℃ + / - 5℃ 2 (g) It was charged to 2.0 Bar. It was stirred for at least 2 hours while maintaining the temperature at 25°C + / - 5°C. It was vented and N2 at 2.0 Bar. (g) Purging was performed. Compound 15 (1.0 eq) was charged into the reactor along with Na2HPO4 (2.3 eq). Methanol (11.0 vol) was charged. The system was closed. At 2.0 Bar, N 2(g) Purged with. H2 at 2.0 Bar (g) It was activated with. H in the container at 25℃ + / - 5℃ 2(g)The solution was charged to 2.0 Bar. The reaction was stirred for approximately 24 hours while maintaining the reaction temperature at 25°C + / - 5°C. Upon complete conversion, 7.7 vol of MeOH was added to dilute the reaction mixture. The reaction mixture was heated to 35.0°C + / - 5°C. The catalyst and Na2HPO4 were removed by filtration. The reactor and filter cake were washed with methanol (4.0 vol), filtered, and combined with the initial filtrate. The Pd content was checked, and resin treatment was performed if necessary (resin treatment: charged with SPM-32 resin (5 wt%)). The resin-treated solution was stirred at 35.0°C + / - 5°C for at least 3 hours. The resin was removed by filtration.
[0621] The reactor and filter cake were washed with methanol (2.0 vol), filtered, and combined with the initial filtrate. Norit CASP activated carbon (3 wt%) was packed. It was stirred at 35.0°C + / - 5°C for at least 3 hours. The activated carbon was removed by filtration. The reactor and filter cake were washed with methanol (2.0 vol), filtered, and combined with the initial filtrate. It was distilled under vacuum to 8.0 vol at below 50°C. Water (2.0 vol) was packed while maintaining the temperature at 45°C + / - 5°C. The resulting slurry was cooled to 0°C + / - 5°C over 2 hours. The slurry was stirred while maintaining it at 0°C + / - 5°C for at least 1 hour. It was filtered, and the cake was washed with 2.0 volume methanol / water (8:2) at 0°C + / - 5°C. 5-amino-4-( Burst -butyl)-2-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)phenylmethyl carbonate (7) was dried under vacuum at 40°C or lower to obtain a white solid, with a purity of >99.5%.
[0622] 4-( Burst -butyl)-2-(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3-d 6 Synthesis procedure of )-5-(4-oxo-l,4-dihydroquinoline-3-carboxamido)phenyl methyl carbonate
[0623]
[0624] The procedure for converting compound 7 to compound 8 can be carried out according to a similar procedure for compound 5 of Example 1 of PCT Publication No. WO 2019 / 109021.
[0625] N -(2-( Burst -butyl)-5-hydroxy-4-(2-(methyl-d 3 )propane-2-yl-1,1,1,3,3,3-d 6 Synthesis procedure of )phenyl)-4-oxo-l,4-dihydroquinoline-3-carboxamide (Dutivacarfter)
[0626]
[0627] 4-( Burst The procedure for converting -butyl)-2-(2-(methyl-d3)propane-2-yl-1,1,1,3,3,3-d6)-5-(4-oxo-l,4-dihydroquinoline-3-carboxamido)phenyl methyl carbonate to dutybacarfter can be carried out according to a similar procedure for the synthesis of compound 1 in Example 1 of PCT Publication No. WO 2019 / 109021.
[0628] Example 5: Preparation of a solid dispersion of Duty Bar Carfter
[0629] Solid dispersions of non-deuterium analogs of duty vakarfter (vakarfter) and methods for preparing such dispersions are disclosed in PCT Publication No. WO 2007 / 079139, which is incorporated herein by reference. These same solid dispersions are suitable for use in duty vakarfter. Alternatively, spray-dried dispersions of duty vakarfter can be prepared using the method described below.
[0630] A mixture of Dutybacarfter, HPMCAS, and SLS (80 wt% Dutybacarfter / 19.5 wt% HPMCAS / 0.5 wt% SLS) was dissolved in a methyl ethyl ketone / water mixture to achieve a total solid load of 11%. The resulting solution was spray-dried using a Buchi spray dryer under the following conditions:
[0631] Nozzle diameter: 1.52 mm
[0632] Outlet temperature:
[0633] NOR: 50 - 60℃
[0634] DSL: 40 - 70℃
[0635] Cooler temperature:
[0636] NOR: -5.5 - 0℃
[0637] DSL: -5.5 - 5.5℃
[0638] The generated wet spray-dried dispersion was further dried under the following conditions to obtain a duty-free spray-dried dispersion.
[0639] Jacket inlet temperature:
[0640] NOR: ≤ 80℃ for 2 hours, then ≤ 110℃ for ≤ 4 days
[0641] DSL: ≤ 80℃ for 2 hours, then ≤ 110℃ for ≤ 11 days or ≤ 120℃ for ≤ 1 day
[0642] Nitrogen flow rate (NOR: 2.5 - 8.0 m) 3 / time; range: 2.5 - 8.0 m 3 / hour)
[0643] Vacuum pressure (NOR: ≤ -0.90 barg; Range: ≤ -0.80 barg)
[0644] Example 6: Preparation of Exemplary Formulation 1
[0645]
[0646] Banjacafter calcium salt hydrate form D, Tejacafter SDD, Dutivacafter SDD, colloidal silicon dioxide, and sucralose were weighed, sieved, and mixed. Separately, lactose monohydrate, mannitol, and croscarmellose were weighed, sieved, and mixed. Then, the two mixtures were combined. Magnesium stearate was weighed, sieved, and mixed with the resulting mixture. Then, the resulting mixture was compressed into granules, the granules were filled into HPMC capsules / sachets, and the filled capsules / sachets were packaged. The target weight of each granule was 7.0 mg, and the average target weight of 10 granules was 70.0 mg.
[0647] Example 7: Preparation of Exemplary Formulation 2
[0648]
[0649] Granules were prepared according to the procedure of Example 6.
[0650] Example 8: Preparation of Exemplary Formulation 3
[0651]
[0652] Granules were prepared according to the procedure of Example 6.
Claims
Claim 1 A pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each of the granules is a. Crystalline Banjacarpter calcium salt hydrate form D;b. A solid dispersion comprising an amorphous Tejacarfter and a first polymer; c. A solid dispersion comprising an amorphous duty barcarfter and a second polymer; d. One or more fillers; e. Disintegrant; f. Sweetener; g. Lubricant; and h. A pharmaceutical composition comprising a lubricant; wherein the unit dosage form comprises an amount of crystalline banzakafter calcium salt hydrate form D in the range of about 1 mg to about 12.7 mg, an amount of amorphous tezakafter in the range of about 10 mg to about 50 mg, and an amount of amorphous dutybakafter in the range of about 15 mg to about 150 mg. Claim 2 A pharmaceutical composition according to claim 1, wherein the unit dosage form comprises about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of amorphous tezakafter, and about 50 mg of amorphous dutivakafter. Claim 3 A pharmaceutical composition according to claim 1, wherein the unit dosage form comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutivakafter. Claim 4 A pharmaceutical composition according to claim 1, wherein the unit dosage form comprises about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of amorphous tezakafter, and about 100 mg of amorphous dutivakafter. Claim 5 A pharmaceutical composition according to claim 1, wherein the unit dosage form comprises about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of amorphous tezakafter, and about 150 mg of amorphous dutivakafter. Claim 6 A pharmaceutical composition according to any one of claims 1 to 5, wherein the first polymer in the solid dispersion containing tezakarfter is HPMC. Claim 7 A pharmaceutical composition according to any one of claims 1 to 6, wherein the second polymer in the solid dispersion containing the duty barcarfter is HPMCAS. Claim 8 A pharmaceutical composition according to any one of claims 1 to 7, wherein the solid dispersion comprising tezakarfter and the first polymer comprises about 80 percent amorphous tezakarfter based on the weight of the dispersion and about 20 percent HPMC based on the weight of the dispersion. Claim 9 A pharmaceutical composition according to any one of claims 1 to 8, wherein the solid dispersion comprising the duty barcarfter and the second polymer comprises about 80 percent amorphous duty barcarfter based on the weight of the dispersion, about 19.5 percent HPMCAS based on the weight of the dispersion, and about 0.5 percent SLS based on the weight of the dispersion. Claim 10 A pharmaceutical composition according to any one of claims 1 to 9, wherein one or more fillers comprise mannitol. Claim 11 A pharmaceutical composition according to claim 10, wherein the mannitol is present in an amount of about 10 to about 14 percent based on the weight of the composition. Claim 12 A pharmaceutical composition according to any one of claims 1 to 11, wherein one or more fillers comprise lactose. Claim 13 A pharmaceutical composition according to claim 12, wherein the lactose is present in an amount of about 35 to about 40 percent based on the weight of the composition. Claim 14 A pharmaceutical composition according to any one of claims 1 to 13, wherein the filler is a binary filler comprising mannitol and lactose. Claim 15 A pharmaceutical composition according to claim 14, wherein the binary filler comprises mannitol to lactose in a weight ratio selected from 1 to about 5, 1 to about 4, 1 to about 3, 1 to about 2, and 1 to about 1.
5. Claim 16 A pharmaceutical composition according to claim 14, wherein the binary filler comprises mannitol to lactose in a weight ratio of 1 to about 3. Claim 17 A pharmaceutical composition according to claim 14, wherein the binary filler comprises mannitol to lactose in a weight ratio selected from 1 to 5, 1 to 4, 1 to 3, 1 to 2, and 1 to 1.
5. Claim 18 A pharmaceutical composition according to claim 14, wherein the binary filler comprises mannitol to lactose in a weight ratio of 1 to 3. Claim 19 A pharmaceutical composition according to any one of claims 1 to 18, wherein the disintegrant is sodium croscarmellose. Claim 20 A pharmaceutical composition according to claim 19, wherein the croscarmellose sodium is present in an amount of about 6 percent based on the weight of the pharmaceutical composition. Claim 21 A pharmaceutical composition according to any one of claims 1 to 20, wherein the sweetener is sucralose. Claim 22 A pharmaceutical composition according to claim 21, wherein the sucralose is present in an amount of about 1 to about 2 percent based on the weight of the pharmaceutical composition. Claim 23 A pharmaceutical composition according to any one of claims 1 to 22, wherein the lubricant is magnesium stearate. Claim 24 A pharmaceutical composition according to claim 23, wherein the magnesium stearate is present in an amount of about 0.5 to about 2.0 percent based on the weight of the composition. Claim 25 A pharmaceutical composition according to any one of claims 1 to 24, wherein the lubricant is colloidal silicon dioxide. Claim 26 A pharmaceutical composition according to claim 25, wherein the colloidal silicon dioxide is present in an amount of about 0.5 to about 1.5 percent based on the weight of the composition. Claim 27 A pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each of the granules is a. About 1 to about 3 percent of crystalline banjacafter calcium salt hydrate form D,b based on the weight of the above composition. About 8 to about 11 percent of a solid dispersion based on the weight of the above composition - said solid dispersion comprises about 80 percent amorphous tejacarfter and about 20 percent HPMC based on the weight of said solid dispersion -,c. A solid dispersion of about 25 to about 35 percent by weight of the above composition - said solid dispersion comprises about 80 percent amorphous duty barcarfter, about 19.5 percent HPMCAS, and about 0.5 percent SLS by weight of said solid dispersion -,d. About 10 to about 14 percent of mannitol based on the weight of the above composition, e. About 30 to about 40 percent lactose based on the weight of the above composition, f. About 1.5 to about 2.5 percent sucralose, g, based on the weight of the above composition. About 5 to about 7 percent of croscarmellose sodium, h, based on the weight of the above composition. About 0.5 to about 1.5 percent of colloidal silicon dioxide based on the weight of the above composition, and i. A pharmaceutical composition comprising about 0.5 to about 2.0 percent magnesium stearate based on the weight of the above composition. Claim 28 A pharmaceutical composition according to claim 27, wherein the mannitol to lactose is present in a weight ratio of 1 to about 3. Claim 29 In Paragraph 27, a. Approximately 2 percent of crystalline banjacarputer calcium salt hydrate form D,b based on the weight of the above composition. Approximately 9.5 percent of a solid dispersion based on the weight of the above composition - said solid dispersion comprises approximately 80 percent of amorphous Tejacarfter and approximately 20 percent of HPMC based on the weight of said solid dispersion -,c. Approximately 29.8 percent of a solid dispersion by weight of the above composition - said solid dispersion comprises approximately 80 percent amorphous duty barcarfter, approximately 19.5 percent HPMCAS, and approximately 0.5 percent SLS by weight of said solid dispersion -,d. Approximately 12.1 percent of mannitol based on the weight of the above composition, e. Approximately 36.3 percent lactose based on the weight of the above composition, f. About 2.3 percent sucralose, g, based on the weight of the above composition. Approximately 6 percent of sodium croscarmellose, h based on the weight of the above composition. About 1 percent of colloidal silicon dioxide based on the weight of the above composition, and i. A pharmaceutical composition comprising about 1 percent magnesium stearate based on the weight of the above composition. Claim 30 A pharmaceutical composition formulated in a unit dosage form comprising a plurality of granules, wherein each of the granules is j. About 1 to about 3 percent of crystalline banjacafter calcium salt hydrate form D,k based on the weight of the above composition. About 8 to about 11 percent of a solid dispersion based on the weight of the above composition - said solid dispersion comprises 80 percent amorphous Tejakafter and 20 percent HPMC based on the weight of said solid dispersion -,l. About 25 to about 35 percent by weight of the above composition, a solid dispersion - said solid dispersion comprises 80 percent amorphous duty barcarfter, 19.5 percent HPMCAS, and 0.5 percent SLS by weight of said solid dispersion -,m. About 10 to about 14 percent of mannitol based on the weight of the above composition, n. About 30 to about 40 percent lactose based on the weight of the above composition, o. About 1.5 to about 2.5 percent sucralose based on the weight of the above composition, p. About 5 to about 7 percent of croscarmellose sodium, based on the weight of the above composition, q. About 0.5 to about 1.5 percent of colloidal silicon dioxide based on the weight of the above composition, and r. A pharmaceutical composition comprising about 0.5 to about 2.0 percent magnesium stearate based on the weight of the above composition. Claim 31 A pharmaceutical composition according to claim 30, wherein the mannitol to lactose is present in a weight ratio of 1 to 3. Claim 32 In paragraph 30, j. Approximately 2 percent of crystalline banjacarputer calcium salt hydrate form D,k based on the weight of the above composition. Approximately 9.5 percent of a solid dispersion based on the weight of the above composition - said solid dispersion comprises 80 percent amorphous Tejacarfter and 20 percent HPMC based on the weight of said solid dispersion -,l. Approximately 29.8 percent of a solid dispersion by weight of the above composition - said solid dispersion comprises 80 percent amorphous duty barcarfter, 19.5 percent HPMCAS, and 0.5 percent SLS by weight of said solid dispersion -,m. Approximately 12.1 percent of mannitol based on the weight of the above composition, n. Approximately 36.3 percent lactose based on the weight of the above composition, o. Approximately 2.3 percent sucralose, p. based on the weight of the above composition. Approximately 6 percent sodium croscarmellose based on the weight of the above composition, q. About 1 percent of colloidal silicon dioxide based on the weight of the above composition, and r. A pharmaceutical composition comprising about 1 percent magnesium stearate based on the weight of the above composition. Claim 33 A pharmaceutical composition according to any one of claims 27 to 32, wherein the unit dosage form comprises about 0.1 to about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 10 to about 50 mg of amorphous tezakafter, and about 15 to about 150 mg of amorphous dutivakafter. Claim 34 A pharmaceutical composition according to any one of claims 27 to 33, wherein the unit dosage form comprises about 4.2 mg of crystalline banzakafter calcium salt hydrate form D, about 16 mg of amorphous tezakafter, and about 50 mg of amorphous dutivakafter. Claim 35 A pharmaceutical composition according to any one of claims 27 to 33, wherein the unit dosage form comprises about 6.4 mg of crystalline banzakafter calcium salt hydrate form D, about 24 mg of amorphous tezakafter, and about 75 mg of amorphous dutivakafter. Claim 36 A pharmaceutical composition according to any one of claims 27 to 33, wherein the unit dosage form comprises about 8.5 mg of crystalline banzakafter calcium salt hydrate form D, about 32 mg of amorphous tezakafter, and about 100 mg of amorphous dutivakafter. Claim 37 A pharmaceutical composition according to any one of claims 27 to 33, wherein the unit dosage form comprises about 12.7 mg of crystalline banzakafter calcium salt hydrate form D, about 48 mg of amorphous tezakafter, and about 150 mg of amorphous dutivakafter. Claim 38 A pharmaceutical composition according to any one of claims 1 to 37, wherein the unit dosage form comprises about 18 to about 60 granules. Claim 39 A pharmaceutical composition according to any one of claims 1 to 38, wherein the unit dosage form comprises about 30 granules. Claim 40 A pharmaceutical composition according to any one of claims 1 to 39, wherein the granules have a shape that is cylindrical, elliptical, conical, spherical, ellipsoidal, polygonal, or a combination thereof, and the longest dimension or diameter of the granules is about 2 mm. Claim 41 A method for treating or reducing the severity of a CFTR-mediated disease in a pediatric patient, comprising the step of administering a pharmaceutical composition of any one of claims 1 to 40 to the pediatric patient. Claim 42 In paragraph 41, the above CFTR-mediated disease is cystic fibrosis, method. Claim 43 A method according to claim 41 or 42, wherein the pharmaceutical composition of any one of claims 1 to 40 is administered once a day. Claim 44 A method according to any one of paragraphs 41 to 43, wherein the patient's weight is about 14 kilograms or more. Claim 45 A method according to any one of paragraphs 41 to 43, wherein the patient's weight is less than about 14 kilograms. Claim 46 A method according to any one of claims 41 to 45, wherein the patient has at least one mutation selected from Table 1. Claim 47 In any one of paragraphs 41 to 45, the patient CFTR A method that is homozygous for the F508del mutation of the gene. Claim 48 A method according to any one of claims 41 to 45, wherein the patient has a heterozygous CFTR genotype and has one F508del mutation. Claim 49 A pharmaceutical composition for use in a method of treating or reducing the severity of a CFTR-mediated disease in pediatric patients, in any one of claims 1 to 40. Claim 50 A pharmaceutical composition according to claim 49, wherein the CFTR-mediated disease is cystic fibrosis. Claim 51 In claim 49 or 50, the pharmaceutical composition is a pharmaceutical composition administered once a day. Claim 52 A pharmaceutical composition according to any one of claims 49 to 51, wherein the patient's body weight is about 14 kilograms or more. Claim 53 A pharmaceutical composition according to any one of claims 49 to 51, wherein the patient's body weight is less than 14 kilograms. Claim 54 A pharmaceutical composition according to any one of claims 49 to 53, wherein the patient has at least one mutation selected from Table 1. Claim 55 In any one of paragraphs 49 to 53, the patient CFTR A pharmaceutical composition that is homozygous for the F508del mutation of the gene. Claim 56 A pharmaceutical composition according to any one of claims 49 to 53, wherein the patient has a heterozygous CFTR genotype and has one F508del mutation. Claim 57 A pharmaceutical composition for use in the manufacture of a medicine for treating or reducing the severity of a CFTR-mediated disease in pediatric patients, in any one of claims 1 to 40. Claim 58 A pharmaceutical composition according to claim 57, wherein the CFTR-mediated disease is cystic fibrosis. Claim 59 In claim 57 or 58, the pharmaceutical composition is a pharmaceutical composition administered once a day. Claim 60 A pharmaceutical composition according to any one of claims 57 to 59, wherein the patient's body weight is about 14 kilograms or more. Claim 61 A pharmaceutical composition according to any one of claims 57 to 59, wherein the patient's body weight is less than 14 kilograms. Claim 62 A pharmaceutical composition according to any one of claims 57 to 61, wherein the patient has at least one mutation selected from Table 1. Claim 63 In any one of paragraphs 57 to 61, the patient CFTR A pharmaceutical composition that is homozygous for the F508del mutation of the gene. Claim 64 A pharmaceutical composition according to any one of claims 57 to 61, wherein the patient has a heterozygous CFTR genotype and has one F508del mutation.
